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 Abstract  
Cancer is a leading cause of death, and tumorigenesis is dependent on different mechanisms, 
including genomic changes and the immune system. Silencing of tumor suppressor genes is an 
important mechanism. The recently suggested tumor suppressor gene, NDRG2, has been 
correlated with down-regulation and decrease proliferation in cancers. Additionally, chronic 
inflammation and cancer development have been connected. Oncogenic transformation occurs in 
tumor cells exposed to repeated chronic inflammation, which may lead to epigenetic alterations 
and changed expression of tumor suppressor genes. The immune system supplies the tumor 
environment with cytokines including IL-6, which has been connected with chronic inflammation 
through its ability to activate STAT3 leading to inhibition of anti-tumor immunity. NDRG2 
expression has been reported to modulate SOCS3 and STAT3 activity and further induce SOCS1 
expression, which leads to down-regulation of STAT3 in breast cancer. It would therefore be 
interesting to study a possible connection between NDRG2 expression and IL-6 levels in colon 
cancer cells. 
The objective of this thesis was to study the expression of NDRG2 and examine a possible 
correlation between IL-6 and NDRG2 expression in colon cancer cell lines, SW480 and HCT116, by 
use of RT-qPCR and western blotting. Furthermore, distinct growth assays were performed to 
evaluate the effect on the growth rate in colon cancer cells of presence of IL-6 and NDRG2, 
separately and together.   
The expression of NDRG2 in colon cancer cells was found to be down-regulated both on mRNA 
and protein level, and the same was observed after treatment with IL-6 on mRNA level. The 
growth assays provided results indicating that SW480 cells transfected with the plasmid pcDNA6-
NDRG2L-V5 had an increased growth rate, when compared with normal SW480 cells, and the 
same tendency was seen after treatment with IL-6, both in normal SW480 cells and transfected 
SW480 cells.  
Altogether, these results suggest that NDRG2 is down-regulated in both colon cancer cell lines, 
and that transfected cells treated with IL-6 show increased growth rate. This may indicate a 
potential correlation between NDRG2 and IL-6 in relation to growth in colon cancer cells.   
 
 
 Resume  
Cancer er en af de hyppigste dødsårsager, og udviklingen af tumorer er afhængig af forskellige 
mekanismer, inklusiv genom-ændringer og immunsystemet. Inhibition af tumor suppressor gener 
er en vigtig mekanisme, og den nyligt foreslåede tumor suppressor kandidat, NDRG2, er blevet set 
nedreguleret i mange forskellige cancer typer og forbundet med nedsat vækst hos cancer celler. 
Endvidere er kronisk inflammation og cancer udvikling blevet forbundet gennem transformation af 
tumor celler, der har været udsat for gentagen kronisk inflammation, hvilket har medført 
epigenetiske ændringer og ændring i udtrykket af tumor suppressor gener. Immunsystemet 
supplerer tumormiljøet med cytokiner, herunder IL-6, som er blevet forbundet med kronisk 
inflammation gennem dets evne til at aktivere STAT3 og medføre inhibition af anti-tumor respons. 
NDRG2 ekspression har vist sig at medføre modulation af SOCS3 og STAT3s aktivitet, og derudover 
induceres ekspressionen af SOCS1, hvilket medfører en nedregulering af STAT3 i bryst cancer. 
Derfor vil det være yderst interessant at undersøge, om der er en mulig forbindelse mellem 
NDRG2 ekspression og IL-6 niveau i colon cancer celler.  
 Formålet med dette speciale var at undersøge ekspressionen af NDRG2 på mRNA og protein 
niveau og undersøge om en mulig sammenhæng mellem IL-6 og NDRG2 ekspression er til stede i 
cancer cellelinierne SW480 og HCT116 ved at bruge metoder som RT-qPCR og western blot. 
Derudover blev vækstforsøg udført for at undersøge om IL-6 og NDRG2, adskilt og sammen, 
påvirker væksten af SW480 celler.  
En nedregulering af NDRG2 ekspression på både mRNA og protein niveau blev fundet i cancer 
celler, og det samme blev observeret på mRNA niveau efter behandling med IL-6. Resultaterne af 
de udførte vækstforsøg viste, at SW480 cellers, transfekteret med plasmid pcDNA6-NDRG2L-V5, 
vækst er øget i forhold til normale SW480 celler og den samme tendens kunne ses efter 
behandling med IL-6 i både normale og transfekteret SW480 celler. Disse resultater indikerer, at 
NDRG2 er nedreguleret i begge cancer cellelinier, og at transfekterede SW480 celler behandlet 
med IL-6 viser en øget vækst, hvilket kunne indikere en potentiel forbindelse mellem NDRG2 og IL-
6 i forhold til væksten af colon cancer celler.  
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1. Introduction  
1.1 Cancer  
According to the WHO, cancer affected 54.9 million people worldwide in year 2012. Cancer is the 
term for a large group of diseases with different origins in the body, and they are also called 
neoplasms [WHO, 2014]. Neoplasia refers to new tissue composed by cells with heritable capacity 
to do uncontrolled and abnormal growth beyond normal growth patterns [Halazonetis et al., 
2008]. Neoplasia exists in two types; malign and benign, where the malign neoplasia is also named 
cancer [Halazonetis et al., 2008]. The process of neoplasia in humans is a multistep process, and 
genetic and epigenetic modifications are highly involved in the transformation of normal cells into 
cancer cells [Hanahan & Weinberg, 2000; Iacobuzio-Donahue, 2009; Baylin & Ohm, 2006]. Cancer 
is caused by alterations in three types of genes, including oncogenes, tumor suppressor genes, and 
stability genes, and unlike most other genetic-dependent diseases, cancer does not arise because 
of a single gene defect [Vogelstein & Kinzler, 2004]. Cancer can be defined as a hyper-proliferative 
disorder and involves morphological cellular transformation, uncontrolled cellular proliferation, 
dysregulation of apoptosis, invasion, angiogenesis, and metastasis [Lin & Karin, 2007; Zitvogel et 
al., 2006]. Hanahan & Weinberg’s six hallmarks constitute and provide understanding of the 
diversity in the processes behind cancer [Hanahan & Weinberg, 2011].  
1.2 The hallmarks of cancer  
Six hallmarks (see Figure 1) that 
describe cancer were proposed in 
2000 by Hanahan & Weinberg to 
support the description of the 
processes behind the development 
of cancer cells and the complexity of 
the tumor tissue [Hanahan & 
Weinberg, 2011]. The hallmarks will 
be described more thoroughly in the 
next sections.   
Figure 1 shows the six hallmarks of cancer [Hanahan & Weinberg, 2011] 
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1.2.1 Sustaining proliferative signaling  
Under normal conditions the production and release of growth-promoting signals are strictly 
controlled by several mechanisms. These control mechanisms ensure homeostasis of cell number 
and maintenance of normal tissue structure and function [Clarke & Fuller, 2006; Hanahan & 
Weinberg, 2011]. Cancer cells are characterized by their ability to sustain proliferative signaling 
and avoid normal growth patterns. They obtain the capability to sustain proliferative signaling in 
several ways including; production of growth factor ligands, stimulation of normal cells to produce 
and release growth factors, de-regulation of receptor signaling, and structural alteration of 
receptor molecules [Cheng et al., 2008; Bhowmick et al., 2004; Hanahan & Weinberg, 2011]. DNA 
sequencing of cancer cells genomes has shown somatic mutations in almost all human tumors, 
and they may affect the constitutive activation of signaling pathways trigged by activated growth 
factor receptors and thus support sustained proliferative signaling [Stratton et al., 2009; Hanahan 
& Weinberg, 2011]. Furthermore, the importance of negative-feedback loops has been shown, 
and under normal conditions they function by suppressing various types of signaling to ensure 
homeostasis in the regulation of signaling through the intracellular circuitry. However, in cancer 
cells defects in these negative-feedback loops enable them to enhance proliferative signaling 
[Hanahan & Weinberg, 2011; Wertz & Dixit, 2010; Cabrita & christofori, 2008; Amit et al., 2007; 
Mosesson et al., 2008].  
1.2.2 Evading growth suppressors  
Just like the controlled production and release of growth factor signals, cell proliferation is 
negatively regulated by specific programs, and many of them depend on the actions of tumor 
suppressor genes [Hanahan & Weinberg, 2011]. Tumor suppressor genes are characterized by 
their ability to prevent proliferation and growth of tumor cells, and studies have shown that they 
are inactivated in many human cancer types [Park & Vogelstein, 2003]. One of the most well-
documented tumor suppressor genes is TP53, which receives signals from stress and abnormality 
sensors and then suppress further cell cycle progression until the right conditions are present. 
Furthermore, TP53 can trigger the cell to undergo apoptosis, whenever irreparable or 
overwhelming damage is observed [Macleod, 2000; Vogelstein et al., 2000; Oren, 2003]. Another 
important tumor suppressor gene is the RB gene encoding the retinoblastoma-associated (RB) 
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protein, which also functions as a central part of the control mechanisms in growth and cell 
division. The RB protein determines if the cell may proceed through the cell cycle, and defects 
found in this pathway are connected with permitted persistent cell proliferation in cancer cells 
[Burkhart & Sage, 2008; Deshpande et al., 2005; Sherr & McCormick, 2002]. Several studies have 
indicated that both TP53 and RB operate through larger networks. Experiments with TP53 null 
mice confirm this redundancy in that they show normal development, tissue homeostasis, and 
proper cell development [Ghebranious & Donehower, 1998].   
Contact inhibition is observed in normal cells and is a consequence of cell-to-cell contact in cell 
populations, where two-dimensional cultures are formed. In various types of cancer this 
mechanism disappears during the course of tumorigenesis, which suggests that contact inhibition 
ensures normal tissue homeostasis in normal cells [Hanahan & Weinberg, 2011]. One of the 
mechanisms involved in contact inhibition is through the protein product of NF2. When the 
expression of the NF2 gene is lost, the formation of neurofibromatosis is trigged. By coupling of 
cell-surface adhesion molecules to the transmembrane receptor tyrosine kinases, the adhesivity of 
cell-to-cell attachments is strengthened and the ability to release mitogenic signals is limited by 
isolation of growth factor receptors [Curto et al. 2007; Okada et al., 2005].  
1.2.3 Resisting cell death 
Normal programmed cell death serves as a natural barrier to cancer development, but elevated 
levels of oncogene signaling can result in signaling imbalances and lead to hyperproliferation 
[Adams & Cory, 2007; Lowe et al., 2004; Evan & Littlewood, 1998]. The apoptotic machinery is 
regulated by both extracellular death-inducing signals (the extrinsic apoptotic program) and 
signals of intracellular origin (the intrinsic apoptotic program). Both signaling programs induce 
activation of proteases, which leads to initiation of a cascade of proteolysis, and the cell is 
progressively disassembled and consumed by neighboring cells [Adams & Cory, 2007; Hannahan & 
Weinberg, 2011]. Regulatory proteins of the B-Cell lymphoma 2 (Bcl-2) family function as 
controllers of apoptotic triggers, and they are inhibitors of apoptosis by binding to the 
proapoptotic triggering proteins, Bcl-2 associated X protein (Bax) and Bcl-2 antagonist/Killer 
protein (Bak). When no proapoptotic proteins are present, Bax and Bak disrupt the integrity of the 
outer mitochondrial membrane, which leads to release of proapoptotic signaling proteins 
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including cytochrome c. A cascade of caspases is activated by cytochrome c and induces the 
cellular changes leading to apoptosis [Adams & Cory, 2007; Willis & Adams, 2005]. Furthermore, 
several abnormality sensors involved in tumor development have been identified and associated 
with apoptosis [Adams & Cory, 2007; Lowe et al. 2004]. The most well-known DNA-damage 
sensors function through the TP53 tumor suppressor and induce apoptosis by up-regulation of 
Noxa and Puma BH3-only proteins, when DNA breaks and chromosomal abnormalities are 
detected [Junttila & Evan, 2009]. Tumor cells have developed several strategies to avoid apoptosis 
and the most common one is the loss of TP53 tumor suppressor function [Hanahan & Weinberg, 
2011].   
Autography is another cell degenerating mechanism, which is induced by cellular stress especially 
at low levels of nutrient, where it enables cells to break down cellular organelles leading to 
recycling for use in biosynthesis and energy metabolism [Levine & Kromer, 2008; Mizushima, 
2007]. Cancer cells are able to generate metabolites that support survival in stressed nutrient-
limited environments and ensure further proliferation of cancer cells [Hanahan & Weinberg, 
2011].  
Necrosis of cells is described as the system-wide exhaustion and breakdown, which leads to 
release of proinflammatory signals to the surrounding microenvironment. As a consequence of the 
proinflammatory signals, inflammatory cells of the immune system are recruited, and this process 
has recently been associated with tumor promotion by inducing angiogenesis, proliferation, and 
invasiveness [Grivennikov et al., 2010; White et al., 2010; Galluzzi & Kroemer, 2008].             
1.2.4 Enabling replicative immortality 
Under normal conditions, cells are only able to pass through a limited number of cell cycles to 
prevent uncontrolled cell proliferation and tumorigenesis [Wai, 2004]. At the end of every 
chromosome are protective structures called telomeres, which are composed of long repetitive 
sequences of TTAGGG [Wai, 2004]. The protection of the chromosomes by telomeres indicates 
that telomeres may be involved in unlimited proliferation and thus connected with cancer 
development [Blasco, 2005; Shay & Wright, 2000]. Senescence and crisis are the two telomere-
dependent pathways of cell mortality, which prevent proliferation and involve irreversible 
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entrance into the cell cycle and cell death [Hanley, 2008]. The first step to prevent further 
proliferation is induction of senescence, and for those cells that succeed in circumventing this 
barrier, the crisis phase will be induced and the cells will undergo cell death. Unlimited 
proliferation has been associated with telomerase activity and expression in immortalized cells 
[Wai, 2004]. Both senescence and crisis are suppressed by telomerase activity, and suppression of 
telomerase activity thus leads to shortening of telomeres and activation of senescence or crisis 
[Hanahan & Weinberg, 2011]. Up-regulation of telomerase expression is the most common 
procedure in immortalized cells to maintain telomeric DNA at lengths sufficient to prevent 
senescence or apoptosis. Excessive or unbalanced oncogene signaling has been shown to induce 
another form of cell senescence and function as a protective mechanism against development of 
neoplasia. Thereby cell senescence is a part of the protective barrier against neoplastic expansion 
and is triggered by various proliferation-associated abnormalities and shortening of telomeres 
[Hanahan & Weinberg, 2011].    
1.2.5 Inducing angiogenesis 
Angiogenesis is the process whereby new blood vessels are developed from existing ones. This 
process is especially used by tumors to acquire nutrients and oxygen, and to evacuate waste 
products and carbon dioxide. Under normal conditions angiogenesis is activated in processes like 
wound healing, but only temporary [Hanahan & Weinberg, 2011]. In tumor progression, 
angiogenesis is almost always activated and new vessels are developed to support the neoplastic 
growth [Hanahan & Folkman, 1996]. This change in the activation of angiogenesis is called the 
angiogenic switch and is controlled by countervailing factors that either induce or oppose 
angiogenesis [Baeriswyl & Christofori, 2009; Bergers & Benjamin, 2003]. The regulation is 
performed by signaling proteins, which bind to cell-surface receptors on vascular endothelial cells. 
These regulatory proteins are classified as either inhibitor or stimulator proteins, and the most 
well-known are vascular endothelial growth factor-A (VEGF-A) and thrombospondin-1 (TSP-1) 
[Hanahan & Weinberg, 2011]. VEGF-A is a stimulator of angiogenesis and has been found to be up-
regulated by oncogene signaling and hypoxia, which indicate an important role in tumor 
progression [Ferara, 2009; Mac Gabhann & Popel, 2008; Carmeliet, 2005]. Additional signaling 
proteins have been associated with tumor angiogenesis based on their proangiogenic properties 
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and chronic up-regulation [Baeriswyl & Christofori, 2009]. TSP-1 and several other proteins have 
been connected with inhibition of angiogenesis and are called endogenous inhibitors of 
angiogenesis [Ribatti, 2009; Kazerounian et al., 2008; Folkman, 2006; Folkman, 2002; Nyberg et al., 
2005]. Many of these proteins can be detected in the circulation in both mice and humans and if 
the levels are increased by overexpression, tumor growth is impaired; this indicates a role as an 
intrinsic barrier to induction of angiogenesis [Ribatti, 2009; Nyberg et al., 2005].  
Cells originating from the bone marrow have been shown to be important in the process of 
angiogenesis [Qian & Pollard, 2010; Zumsteg & Christofobi, 2009; Murdoch et al., 2008; De Palma 
et al., 2007]. Many cells from the innate immune system originate from the bone marrow 
including macrophages, neutrophils, mast cells, and myeloid progenitors, and all of them are able 
to infiltrate the tumor environment. These cells are also involved in the angiogenic switch, which 
occurs in the early progression of the tumor and ensures facilitation of local invasion [Hanahan & 
Weinberg, 2011]. After the migration to the neoplastic environment most of the bone marrow-
derived progenitor cells become pericytes or endothelial cells. Studies have shown an association 
between pericytes and the neovasculature found in most tumors, where pericytes are important 
for the maintenance of functional tumor neovasculature [Patenuade et al., 2010; Kovacic & 
Boehm, 2009; Lamagna & Bergers, 2006; Raza et al., 2010; Bergers & Song, 2005].        
1.2.6 Activating invasion and metastasis  
Invasion and metastasis is a multistep process and is termed the invasion-metastasis cascade 
[Talmadge & Fidler, 2010; Fidler, 2003]. Local invasion of the specific tissue is the first step, 
followed by intravasion into blood and lymphatic vessels, which makes the cancer cells able to 
escape through the lymphatic and hematogenic systems and invade distant tissues. When the 
cancer cells have reached the distant tissue, the formations of small nodules of cancer cells 
(micrometastases) takes place and by further growth they develop into macroscopic tumors 
[Hanahan & Weinberg, 2011].  
The ability of cancer cells to invade and develop metastases involves alterations in shape and 
attachment to other cells and the extracellular matrix (ECM). A well-known key cell-to-cell 
adhesion molecule is E-cadherin, and the expression of this molecule has been found to be missing 
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in carcinoma cells. E-cadherin works by forming junctions with adjacent epithelial cells to 
assemble and maintain epithelial cell sheets, and the down-regulation of E-cadherin in carcinomas 
support its role as a key suppressor of invasion and metastasis [Berx & van Roy, 2009; Cavallaro & 
Christofori, 2004]. The gene expression of many cell-to-ECM adhesion molecules has been found 
altered in aggressive forms of carcinomas and especially adhesion molecules involved in cell 
migration are up-regulated [Cavallaro & Christofori, 2004].  
Epithelial cells become transformed by epithelial-mesenchymal transition (EMT) to acquire the 
ability to invade, resist apoptosis, and disseminate [Klymkowsky & Savagner, 2009; Polyak & 
Weinberg, 2009; Thiery et al., 2009; Yilmaz & Christofori, 2009; Barrallo-Gimeno & Nieto, 2005]. 
Carcinoma cells are able to co-opt multiple attributes from the EMT program, which enable the 
invasion and metastasis, and further carcinoma cells can activate the EMT program transiently or 
stably throughout the invasion and metastasis. The activation of EMT is organized by several 
transcriptional factors, which are all expressed in different combinations in different malignant 
tumor types [Micalizzi et al., 2010; Taube et al., 2010; Schmalhofer et al., 2009; Yang & Weinberg, 
2008]. These transcription factors affect the cells by loss of adherence junctions, expression of 
matrix-degrading enzymes, increased motility, and resistance to apoptosis, all processes involved 
in invasion and metastasis [Hanahan & Weinberg, 2011]. The gene expression of E-cadherin has 
been found repressed by several of these transcription factors, which lead to increased 
invasiveness in the neoplastic epithelial cells [Peinado et al., 2004].  
The collaboration between cancer cells and cells of the neoplastic stroma has been shown to be 
strongly associated with the ability of cancer cells to invade and develop metastases [Egeblad et 
al., 2010; Qian & Pollard, 2010; Joyce & Pollard, 2009; Kalluri & Zeisberg, 2006]. Experiments with 
metastatic breast cancer have shown collaboration between tumor-associated macrophages 
(TAMs) and breast cancer cells, where TAMs supply the cancer cells with epidermal growth factor 
(EGF), and the cancer cells supply TAMs with CSF-1. Intravasion into the circulatory system and 
development of metastases happen through this communication between normal cells and cancer 
cells [Qian & Pollard, 2010; Wyckoff et al., 2007].    
The invasion process can be split up in to different modes; collective invasion and amoeboid 
invasion [Friedl & Wolf, 2008; Friedl & Wolf, 2010]. Collective invasion is when a small mass of 
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cancer cells invades an adjacent tissue, and this type of invasion is characteristic for squamous cell 
carcinomas. Individual cancer cells can also perform invasion typically in already existing 
interstices in the extracellular matrix, but the knowledge about this amoeboid invasion is limited 
[Madsen & Sahai, 2010; Sabeh et al., 2009]. Inflammatory cells have been shown to produce 
extracellular matrix-degrading enzymes and other important factors and thereby facilitate cancer 
cell invasion and growth [Kessenbrock et al., 2010; Qian & Pollard, 2010; Joyce & Pollard, 2009]. 
The cancer cells recruit the inflammatory cells by release of chemoattractants, and thus they avoid 
producing the matrix-degrading enzymes themselves [Hanahan & Weinberg, 2011].  
After the invasion the next step is the development of metastases, which can be described by two 
phases; the dissemination of cancer cells from the primary tumor to distant tissues, and the 
successful colonization leading to development of micrometastases into macroscopic tumors 
[Hanahan & Weinberg, 2011]. The development from micrometastases to macroscopic tumors can 
be controlled by systemic suppressor factors, which are released by the primary tumor in some 
cancer types [Demicheli et al., 2008; Folkman, 2002]. In those cases, when the primary tumor is 
removed the metastatic growth will explode and the macroscopic tumor develop as a 
consequence of the missing systemic suppressor factors [Demicheli et al., 2008; Folkman, 2002]. 
Other reasons for delayed development of micrometastases are inability to activate tumor 
angiogenesis, antigrowth signals, tumor suppression by the immune system, nutrient starvation 
inducing autophagy, and poor adaption to new microenvironments in the tissue [Naumov et al., 
2008; Aguirre-Ghiso, 2007; Kenific et al., 2010; Lu et al., 2008; Barkan et al., 2010; Teng et al., 
2008; Gupta et al., 2005].     
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1.3 Enabling characteristics and emerging hallmarks in cancer  
Hanahan & Weinberg have proposed some emerging hallmarks and enabling characteristics of the 
development of cancer [Hanahan & Weinberg, 2011]. Enabling characteristics make the process of 
tumorigenesis possible, and these 
characteristics describe how the 
development of cancer cells occurs. 
Emerging hallmarks ensure the 
progression of the cancer cells by 
deregulation of cellular energetics and 
the ability to avoid immune 
destruction, see Figure 2 [Hanahan & 
Weinberg, 2011]. Throughout this 
master thesis, the main focus will be on 
genome instability and mutations, 
avoiding immune destruction, and 
tumor-promoting inflammation. 
1.3.1 Genome instability and mutations  
The first enabling characteristic for cancer development discovered was genome instability and 
mutations, which trigger tumor progression [Hanahan & Weinberg, 2011]. Clonal expansion can be 
achieved through changes in the genome and are caused by genetic and epigenetic mechanisms 
including inactivation of different cancer related genes [Berdasco & Esteller, 2010; Esteller, 2007; 
Jones & Baylin, 2007; De Visser et al., 2006; Abbas et al., 2007; Jones, 2007; Shama et al., 2010].  
Normally, the genome’s maintenance system is able to detect and resolve defects in the DNA and 
thus ensure low rate of spontaneous mutations during each cell generation, but cancer cells are 
capable of modifying the maintenance system and increase the rate of mutations in order to 
ensure the development of tumorigenesis [Negrini et al., 2010; Salk et al., 2010]. By breakdown in 
one or several components of the genomic maintenance machinery, the genome becomes more 
sensitive to mutagenic agents and as a result the mutation rate is increased. The surveillance 
Figure 2 shows the enabling and emerging hallmarks of cancer [Hanahan 
& Weinberg, 2011] 
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systems of the genome normally monitor genomic integrity and force damaged cells into either 
senescence or apoptosis, but the altered mutation rate can compromise these systems and 
accumulation of mutations is accelerated [Jackson & Bartek, 2009; Kastan, 2008; Sigal and Rotter, 
2000]. A special group of genes of the DNA-maintenance machinery are named caretakers of the 
genome and defects in these genes and theirs products are involved in detection of DNA damage, 
activation of the repair system and direct repair of damaged DNA, and inactivation of mutagenic 
molecules before damaged DNA [Kinzler & Vogelstein, 1997; Negrini et al., 2010; Ciccia & Elledge, 
2010; Jackson & Bartek, 2009; Kastan, 2008; Harper & Elledge, 2007; Friedberg et al., 2006].  
Introduction of mutant copies of these caretaker genes into mice results in increased cancer 
incidence and thus supports their involvement in human cancer development [Barnes & Lindalh, 
2004]. Both genetic and epigenetic modifications drive the tumor progression, and the large 
numbers of defects in genes of the maintenance and repair systems together with findings of 
silencing of tumor suppressor genes are all supporting the enabling characteristic of genome 
instability in cancer development [Hanahan & Weinberg, 2011].  
1.3.2 Genetic modifications in the genome of cancer cells  
Genomic instability is characteristic for almost all human cancer types and is caused by genetic 
modifications [Negrini et al., 2010; Stratton et al., 2009]. Different forms of genomic instability are 
found, and the most common form in human cancer is called chromosomal instability (CIN), which 
refers to a high rate of changes found in chromosome structure and number, when cancer cells 
are compared with normal cells [Negrini et al., 2010; McGranahan et al., 2012]. Other forms of 
genomic instability have been found, including forms that are characterized by expansion or 
contraction of the number of oligonucleotide repeats present in microsatellite sequences, and 
increased frequencies of base-pair mutations [Fisher et al., 1993; Leach et al., 1993; Al-Tassan et 
al., 2002].  
Cancer types can be classified as hereditary or sporadic cancers depending on their origin and 
development. Both CIN and non-CIN forms of genomic instability have been associated with 
mutations in DNA repair genes and are characteristic for hereditary cancers [Fishel et al., 1993; 
Negrini et al., 2010]. The study of mutations in DNA repair genes in hereditary cancers has 
provided evidence for the mutation hypothesis concerning the presence of genomic instability in 
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precancerous lesions and increased mutation rate leading to tumor development [Nowell, 1976; 
Loeb, 1991]. As mentioned earlier, genomic instability has been linked to mutations in caretaker 
genes, and they include DNA repair genes and mitotic checkpoint genes. Furthermore, the tumor 
suppressor gene TP53 and ataxia telangiectasia mutated gene have been considered as caretaker 
genes because of their function in DNA damage responses [Negrini et al., 2010].  The presence of 
genomic instability caused by inactivation of caretaker genes in sporadic cancers has not been 
confirmed successfully, and the molecular basis of genomic instability in sporadic cancers is still 
unclear [Negrini et al., 2010]. Several studies have investigated target sequences hoping to find 
mutations in DNA repair and mitotic checkpoint genes with higher mutation frequency, and 
thereby explain the genomic instability and development of sporadic cancers [Rajagopalan & 
Lengauer, 2004; Cahill et al., 1999; Wang et al., 2004; Cahill et al., 1998]. The low frequency of 
mutations in caretaker genes observed in sporadic cancers may be underestimated because of the 
repression of gene function caused by epigenetic mechanisms [Esteller, 2008]. These epigenetic 
abnormalities together with genetic alterations are important processes in the transformation of 
normal cells to cancer cells [Sharma et al., 2010].  
1.3.3 Epigenetics 
All DNA in cells is packaged into chromatin forms, and these structures define the state of 
organization of genetic information within the cell [Sharma et al., 2010]. The chromatin structure 
is made by nucleosomes, where every unit contains 146 base pairs of DNA. The DNA is wrapped 
around a histone octamer 
consisting of four histone 
proteins, named H3, H4, 
H2A, H2B, see Figure 3 
[Luger et al., 1997;  
Iacobuzio-Donahue, 2009; 
Momparler, 2003]. 
 Epigenetics was defined by 
C.H. Waddington in the 1940s based on epigenetics in embryonic development. Later the 
definition was modified, so that epigenetic changes mean heritable changes in gene expression 
Figure 3 shows the chromatin structure, nucleosome and histone composition [Füllgrabe  
et al., 2010] 
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which are not accomplished by changes in the primary DNA sequence, and the definition of 
epigenetics is modifications of DNA [Jones & Baylin, 2007; Momparler, 2003; Baylin & Ohm, 2006; 
Iacobuzio-Donahue, 2009; Sharma et al., 2010; Rodriquez-Paredes & Esteller, 2011].  The 
epigenetic processes are essential for key biological processes, such as proper development, 
cellular differentiation, imprinting, and silencing of large chromosomal domains, which include 
histone modifications, genome imprinting, and DNA methylation [Sharma et al., 2010; Rodriquez-
Paredes & Esteller, 2011; Jones & Baylin, 2007; Iacobuzio-Donahue, 2009; Jaenisch & Bird, 2003; 
Momparler, 2003]. Studies have found that genetic and epigenetic alterations interact at all stages 
of cancer development and promote cancer progression [Sharma et al., 2010; Jones & Laird, 
1999]. Epigenetic modifications have further been connected with suppression of tumor 
suppressor genes in several cancer types. Thereby, epigenetic modifications are of highest interest 
for this project because of the connection between cancer development and repression of tumor 
suppressor genes such as the potential tumor suppressor gene, NDRG2.  
1.3.4 Epigenetic changes in normal cells  
The function of the genome is regulated through different epigenetic mechanisms such as DNA 
methylation, histone modification, and miRNAs, which all modify the chromatin structure [Sharma 
et al., 2010]. All these modification mechanisms work together and regulate the genome by 
altering the local structure of chromatin, thereby creating an “epigenome” that ensures the 
cellular identity by the way the genome manifests itself in different cell types [Jones & Baylin, 
2007; Bernstein et al., 2007; Suzuki & Bird, 2008; Kouzarides, 2007; Zhang et al., 2007; Jiang et al., 
2009]. 
Normally, the primary sequence of DNA consists of 
four bases named adenine, guanine, cytosine and 
thymine, but a fifth base called 5-methylcytosine can 
be produced by covalent modification of post-
replicative DNA. This process is also called DNA 
methylation, in which S-adenosyl-methionine 
function as the methyl donor and the process is 
catalyzed by the enzyme DNA methyltransferase (DNMTs). The methylation is finished when the 
Figure 4 shows the DNA methylation process [Meehan, 
2013] 
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methyl group is added to the cytosine ring, see Figure 4, and the cytosine becomes methylated 
[Herman & Baylin, 2003]. The process of DNA methylation takes place after DNA replication and 
cell division, and the process is performed by a maintenance DNA methylase, also called DNMT1 
[Momparler, 2003].  DNA methylation provides stable gene silencing and plays an important role 
in regulation of gene expression [Sharma et al., 2010]. This epigenetic modification primarily 
occurs in cytosines of the dinucleotid sequence CpG, and CpG-rich regions are called CpG islands 
[Herman & Baylin, 2003; Weber et al., 2007; Jaenisch & Bird, 2003]. The distinction between CpG 
sites and CpG islands is based on size, with CpG islands defined as a 1 kb stretch of DNA containing 
the sequence more frequently than the rest of the genome [Momparler, 2003]. CpG islands are 
primarily located in the 5’end of the gene and in 60 % of all human gene promoters, and they are 
normally not methylated in normal cells, whereas CpG sites have been found to be methylated to 
prevent chromosome instability [Herman & Baylin, 2003; Weber et al., 2007; Suzuki & Bird, 2008; 
Wang et al., 2004].   
Another important epigenetic mechanism is histone modification. The histone is composed of four 
core histone proteins with DNA wrapped around them. The nucleosome has an N-terminal tail and 
a C-terminal domain, and the N-terminal tail can undergo many post-translational modifications 
such as methylation, acetylation, ubiquitylation and phosphorylation [Kouzarides, 2007]. All these 
modifications are added or removed by different enzymes, including histone acetyltransferases 
(HATs), deacetylases (HDACs), methyltransferases (HMTs), demethylases (HDMs), and so on 
[Kouzarides, 2007; Allis et al., 2007]. Different combinations of modifications in specific genomic 
regions may lead to a more open or closed state of the chromatin structure, and unlike DNA 
methylation this leads to either activation or repression of the genes [Li et al., 2007; Sharma et al., 
2010]. Furthermore, these specific patterns of histone modifications may play a potential role in 
determining cellular identity by affecting gene expression [Mikkelsen et al., 2007; Ringrose et al., 
2007].  
Interactions between DNA methylation and histone modifications are necessary for each of them 
to perform their individual roles in gene regulation, and the complexity of epigenetic regulation is 
further enhanced by these interactions [Cedar & Bergman 2009]. 
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MicroRNAs (miRNA) are small noncoding RNAs that are able to regulate gene expression through 
posttranscriptional silencing by binding to the 3’ untranslated region of mRNAs [Baer et al., 2013; 
Sharma et al., 2010]. This binding leads to inhibition of protein synthesis or RNA degradation, both 
affecting the expression of the target gene [Baer et al., 2013; He & Hannon, 2004]. Like other 
epigenetic mechanisms, miRNAs are also part of the control of different biological processes, 
including cell proliferation, apoptosis, and differentiation, and the miRNAs can be regulated like 
normal genes by epigenetic modifications [Saito & Jones, 2006]. Furthermore, miRNAs are able to 
modulate epigenetic regulatory mechanisms by targeting enzymes involved in DNA methylation 
and histone modifications [Sharma et al., 2010].      
1.3.5 Epigenetic modifications and cancer  
Several studies have stated the fact that epigenetic changes play an important role in 
tumorigenesis [Momparlet 2003; Sharma et al., 2010; Rodriguez-Paredes & Esteller, 2011]. The 
first connection between epigenetic abnormality and cancer was found by Feinberg and 
Vogelstein in 1983, who observed a reduction in methylation in colon cancer cells when compared 
with normal tissue [Feinberg & Vogelstein, 1983]. Additionally, Gama-Sosa et al. demonstrated a 
reduction of 5-methylcytosine content, and both reductions where observed in pre-invasive and 
invasive cancer tissues [Gama-Sosa et al., 1983]. DNA methylation is a normal event in gene 
regulation, but aberrant DNA methylation can lead to silencing of tumor suppressor genes and 
also to activation of oncogenes, which are two important groups of genes in cancer development 
[Momparlet, 2003; Sharma et al., 2010; Esteller, 2007]. The activation of oncogenes happens by a 
mechanism called DNA hypomethylation, which means loss of methylation, and which can lead to 
demethylation of specific coding regions [Feinberg & Tycko, 2004]. Furthermore, DNA 
hypomethylation differ from the more site-specific DNA hypermethylation by affecting many 
genomic sequences in the genome and thus leading to genomic instability [Esteller, 2007]. The 
degree of hypomethylation increases through the progression of cancer [Fraga et al., 2004]. In 
both gastric cancer and colon cancer, growth-promoting genes such as R-Ras, MAPSIN and S-100 
have been found activated by hypomethylation [Sharma et al., 2010]. Also, promoter regions have 
been found to be demethylated allowing normally repressed genes to become expressed, for 
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example the gene PAX2 known to encode a transcription factor involved in proliferation of cells 
[Wu et al., 2005; Brueckner et al., 2007].  
Opposite to DNA hypomethylation, DNA hypermethylation works by silencing especially tumor 
suppressor genes and thereby inducing cancer progression [Costello et al., 2000; Esteller et al., 
2001]. The first DNA hypermethylations were found in the CpG Island of the promoter region of 
the Rb tumor suppressor gene [Greger et al., 1989; Sakai et al., 1991]. This finding was further 
supported by hypermethylation in other tumor suppressor genes, such as P16, MLH1, VHL (Hippel-
Lindau disease) and BRCA1 (Breast cancer) [Herman & Baylin, 2003; Esteller et al., 2000; Baylin, 
2005; Jones & Baylin., 2002; Jones & Baylin, 2007]. The mentioned tumor suppressor genes are all 
involve in DNA repair, cell cycle control, cell adhesion, apoptosis, and angiogenesis, which are all 
important steps in the cancer development and progression [Sharma et al., 2010; Feinberg, 2005; 
Howard et al., 2008]. DNA hypermethylation of the CpG islands in tumor suppressor genes are 
specific for each cancer type [Esteller et al., 2001; Grady et al., 2000]. How these specific 
hypermethylation “patterns” occur for each cancer type is still unclear. Besides affecting tumor 
suppressor genes, hypermethylation can also indirectly silence genes encoding transcription 
factors and DNA repair genes [Sharma et al., 2010].  
A new potential tumor suppressor gene is NDRG2, which has been found to be involved in cell 
growth, initiation and progression of cancer, cell differentiation, and apoptosis [Shi et al., 2009; 
Yao et al., 2008; Choi et al., 2003]. Down-regulation or inactivation of NDRG2 expression has been 
linked to transcriptional repression by MYC, post-translational inactivation by microRNA, and 
epigenetic silencing through promoter methylation [Oh et al., 2012; Zhang et al., 2006; Shi et al., 
2009; Tepel et al., 2008; Lusis et al., 2005; Piepoli et al., 2009; Furuta et al., 2010; Zhao et al., 
2008; Shi et al., 2009]. Hypermethylation is one of the most important reasons for down-
regulation and loss of NDRG2 expression, and hypermethylation of the NDRG2 promoter is 
significantly associated with meningioma, breast cancer, and colorectal cancer [Yao et al., 2008; 
Feng et al., 2011; Piepoli et al., 2009; Tepel et al., 2008; Liu et al., 2007; Lusis et al., 2005].  
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1.3.6 N-Myc downstream-regulated family of genes    
One of the earliest identified oncogenes was MYC, which has been associated especially with 
regulation of cell proliferation and differentiation. A small fraction of Myc-repressed genes have 
shown the ability to affect the interaction and communication between the cells and their external 
environment, and several of these have been associated with tumor suppressor and metastatic 
properties [Vervoorts et al., 2006; Grandori et al., 2000; Dang, 1999; O’Connell et al., 2003].  One 
of the families of Myc-repressed genes are the N-Myc downstream-regulated family of genes 
(NDRG), which consists of four genes called NDRG1-4 and are all found in humans [Qu et al., 2002; 
Liu, 2012; Yao et al., 2008]. Because of the potential as tumor suppressors, the NDRG gene family 
has been given special attention in cancer research [Yao et al., 2008].  
The NDRG genes are localized on four different chromosomes, and they code for proteins of 
varying sizes ranging from 339 – 394 amino acids, see Table 1 [Lorentzen & Mitchelmore, 2012; 
Zhao et al., 2001]. The sequences of the four genes have sequence homologies between 57 and 65 
% [Lorentzen & Mitchelmore, 2012; Chu et al., 2011; Melotte et al., 2010]. The different isoforms 
of the NDRG genes are uniquely expressed in tissues between species, which is especially apparent 
for NDRG4 in human and mice [Melotte et al., 2010].  
Name  Chromosomal location Isoform  Number of exon Protein length (aa) 
NDRG1 8q24 0 16 394 
NDRG2 14q11.1-11.2 1 
2 
14 
13 
371 
357 
NDRG3 20q11.21-q11.23 1 
2 
16 
15 
375 
363 
NDRG4 16q21-q22.1 1 
2 
3 
17 
16 
15 
371 
352 
339 
Table 1 shows the comparison of human N-myc downstream-regulated gene (NDRG) gene family [Lorentzen & Mitchelmore, 
2012; Melotte et al., 2010; Yao et al., 2008] 
 Common for NDRG proteins is the α/β hydrolase fold domain and NDR-domain, where the α/β 
hydrolase fold domain has showed no catalytic function in any of the genes [Zheng et al.,  2010; 
Lorentzen & Mitchelmore, 2012; Bhaduri et al., 2003; Shaw et al., 2002].  The sequence 
differences are primarily located in the N-and C-terminal regions of the NDRG genes, and NDRG1 
differs from the rest of the genes by having three 10-aa tandem repeats in the C-terminal region, 
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see Figure 5 [Melotte et al., 2010]. All family 
members have a CpG island in their 
promoter, which is an important feature in 
DNA methylation of the genes [Melotte et 
al., 2010].  
All the proteins of the NDRG gene family 
have been correlated with the regulation of 
cell proliferation, differentiation, 
development, and stress responses [Kim et 
al., 2009; Melotte et al., 2010]. The 
function of NDRG1 is the most well-known, 
and alterations in the protein have been observed, when specific mutations are present in the 
gene. Especially two mutations have been linked with Charcot-Marie-Tooth disease, which is also 
known as a demyelinating disorder [Hunter et al., 2003; Kalaydjieva et al., 2000]. NDRG1 
expression is induced by cellular stresses, and it is involved in inflammatory processes, regulation 
of cell growth, metastasis suppression, and nerve myelination [Taketomi et al., 2003; Piquemal et 
al., 1999; Kalaydjieva et al., 2000; Kim et al., 2009]. Important roles in neurodegenerative diseases, 
cell differentiation, and cancer have been found for all genes of the NDRG family, and especially in 
studies on NDRG2 expression, significantly low levels of NDRG2 were found in tumors and cancer 
cell lines, when compared with normal benign tissues. This may indicate a potential role for 
NDRG2 as a tumor suppressor and as a prognostic marker in some cancer types [Lorentzen & 
Mitchelmore, 2012; Wang et al., 2012; Yang et al., 2011; Shi et al., 2009; Lusis et al., 2005; Park et 
al. 2008].    
1.3.7 NDRG2  
Two isoforms of NDRG2 are found located on chromosome 14q 11.1-11.2, and they differ in 
numbers of exons and amino acids, see Table 1 [Dake, 2011 & Libo, 2008; Feng et al., 2011]. In the 
C-terminal region of NDRG2, several potential phosphorylation sites are found, and they may have 
influence on regulatory mechanisms by a phosphorylation-dephosphorylation cycle [Lorentzen et 
al., 2011; Kim et al., 2009; Yao et al., 2008].  
Figure 5 shows the variation between the genes in the NDRG family 
[Melotte et al., 2010] 
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The expression of the NDRG2 gene has been analyzed on mRNA level, and high expression of 
NDRG2 mRNA was found in brain, heart, skeletal muscle, liver, and kidney, and low expression was 
found in colon, spleen, placenta, and lung tissue [Yao et al., 2008; Wang et al., 2012; Feng et al., 
2011; Lorentzen et al., 2011]. The observed expression pattern of NDRG2 suggests a correlation 
between the level of NDRG2 and the rate of cell proliferation, and during development the 
expression level of NDRG2 is increased [Hu et al., 2006]. The protein product of NDRG2 is found in 
cytoplasm, cell membranes, adherence junctions, and the nucleus [Deng et al., 2003; Qu et al., 
2002; Lachat et al.,2002; Hu et al., 2006; Shen et al., 2008; Okuda et al., 2008; Yang et al., 2011]. 
Beside the potential role in cancer development, an up-regulation of NDRG2 has been observed in 
patients with Alzheimer disease and linked with neural differentiation, synapse formation, and 
axon survival [Mitchelmore et al., 2004; Nichols et al., 2005]. NDRG2 is also up-regulated under 
hypoxic conditions in cancer cell lines, which may indicate a role as a cell stress responding 
molecule. This observation is further supported by experiments where NDRG2 silencing reduced 
hypoxia-induced apoptosis suggesting that NDRG2 function as a positive regulator of hypoxia-
induced apoptosis [Melotte et al., 2010; Wang et al., 2008]. Furthermore, NDRG2 has been 
associated with insulin-production, aldosterone-mediated epithelial sodium channel function, and 
dendritic cell differentiation [Choi et al., 2003; Boulkroun et al., 2002; Burchfield et al., 2004; 
Wielpütz et al., 2007].  
As a member of the N-myc downstream-regulated gene family, NDRG2 is transcriptionally 
regulated by Myc, which function as a master switch molecule in cell proliferation and 
differentiation [Dang et al., 2008; Wierstra & Alves, 2008]. Shi et al. have also shown that C-Myc 
can repress human NDRG2, and in experiments with colorectal cancer an increased level of Myc 
was observed, whereas the level of NDRG2 was decreased [Shi et al., 2009]. This may indicate a 
potential role for NDRG2 as an inhibitor of cancer cell proliferation [Shi et al., 2009].    
In several types of cancer, the level of NDRG2 has been found to be decreased or undetectable, 
and these observations may indicate an important role in initiation and progression of cancer cells. 
Supporting the statement of NDRG2 as a tumor suppressor gene, NDRG2 was found to suppress 
cell proliferation, cell survival, and induce apoptosis through regulation of cyclin D1 and T cell 
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factor (TCF)/β-catenin activity [Shi et al., 2009; Lorentzen & Mitchelmore, 2012; Yao et al., 2008; 
Chu et al., 2011; Zheng et al., 2010; Liang et al., 2012].  
1.3.8 NDRG2 & Cancer  
Several experiments have confirmed different expression patterns for NDRG2 in tumors and 
normal tissue [Deng  et al., 2003; Lusis et al., 2005; Lorentzen et al., 2007; Choi et al., 2007; Liu et 
al., 2007; Hu et al., 2004; Assämäki et al., 2007; Felsberg et al., 2006; Hummerich et al., 2006]. The 
connection between low expression of NDRG2 and proliferation of cancer cells was first observed 
in glioblastoma cells, and the NDRG2 expression was reduced by 56 % in human glioblastoma 
tissue, when compared to normal tissue samples [Deng et al., 2003]. Furthermore, Deng et al., 
showed that NDRG2 was able to inhibit proliferation of glioblastoma cells, when NDRG2 was 
expressed in the tissue [Deng et al., 2003]. Down-regulation or absence of NDRG2 expression on 
both mRNA and protein level have been observed in several types of cancer, including colorectal 
cancer, breast cancer, lung cancer, hepatocellular cancer, glioma, oral squamous cell carcinoma, 
thyroid cancer, liver cancer, pancreas cancer, meningioma, clear cell renal cell carcinoma (CCRCC), 
prostate cancer, gallbladder cancer, gastric cancer, and myeloid leukemia [Chu et al., 2011; Hu et 
al., 2004; Lee et al., 2008; Lorentzen et al., 2007; Piepoli et al., 2009; Lorentzen et al., 2011; Zhao 
et al., 2008; Ma et al., 2008;  Wang et al., 2012; Chang et al., 2012]. In addition, nineteen different 
types of cancer tissues have been studied, and an up-regulation of NDRG2 mRNA was only 
observed in around 8 % of the tissues, whereas 62 % of the tissues showed unchanged expression 
of NDRG2 mRNA. Every third sample of cancer tissue tested showed a down-regulation of NDRG2 
expression when compared with normal tissue [Lorentzen et al., 2011].  
In studies of breast cancer, low or no expression of NDRG2 was observed, and this may be of 
importance for the metastatic potential by inducing bone morphogenetic protein 4 (BMP-4) 
expression thereby suppressing matrix metallopeptidase 9 (MMP-9) activity, which has influence 
on metastasis and angiogenesis [Zheng et al., 2010; Lorentzen et al., 2011]. Oh et al. have shown 
clinically that NDRG2 suppresses tumor metastasis by decreasing the active autocrine 
transforming growth factor beta (TGF-β) production, which leads to a significantly higher 
recurrence and survival rate in patients [Oh et al., 2012]. CD24 glycoprotein is expressed on the 
surface of most B lymphocytes and differentiated neuroblasts and function as an adhesion 
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molecule for P-selectin, which is related to tumor growth and metastasis. The CD24/P-selectin 
binding pathway causes interactions with platelets and endothelial cells, which lead to spreading 
of cancer cells. NDRG2 has thereby been identified as a regulator of adhesion and invasion 
processes in breast cancer, hepatocellular carcinoma cancer, lung cancer, and gallbladder 
carcinoma [Zheng et al., 2010; Song et al., 2012; Wang et al., 2012]. Lung cancer studies have also 
shown a correlation between high CD24 levels and metastasis. NDRG2 is highly expressed in the 
early stages of cancer development without any pathological metastasis in lung cancer patients. 
Reduced NDRG2 expression is thereby associated with CD24 up-regulation and poor prognosis in 
breast cancer, lung cancer, hepatocellular carcinoma, and gallbladder carcinoma [Wang et al., 
2012; Zheng et al., 2010; Zheng et al., 2011; Song et al., 2012]. High levels of CD24 have been 
correlated with lymph node metastases, high TNM status, and lower survival rate [Song et al., 
2012].  
Studies with hyperthermia have show changes in invasion capacity and apoptosis rate in both 
hepatocellular carcinoma and gastric cancer [Tao et al., 2013; Guo et al., 2013]. Hyperthermia 
leads to overexpression of NDRG2 by inhibition of MMP-2, MMP-9, and invasion in hepatocellular 
carcinoma. Suppression of MMP-9 is correlated with a higher metastasis rate, but the 
overexpression of NDRG2 suppresses the function of MMP-9 [Guo et al., 2013; Zheng et al., 2010; 
Oh et al., 2012]. Knockdown of NDRG2 expression reverses the effect of the hyperthermia reaction 
by inducing invasion [Guo et al., 2013]. Apoptosis rate in gastric cancer is increased by 
approximately 8.3% after one hour of treatment [Tao et al., 2013].  
In clear cell renal cell carcinoma (CCRCC), NDRG2 has been associated with inhibition of CCRCC cell 
lines growth rates and induction of cell cycle arrest at G1 in vitro [Liang et al., 2012]. Furthermore, 
NDRG2 expression was found to be down-regulated, which has been linked with oncogenic 
properties, and NDRG2 may function as a potential prognostic biomarker. Additionally, the 
decrease in NDRG2 expression has been associated with higher TNM stages [Song et al., 2011; Ma 
et al., 2012; Liang et al., 2012].  
Metastasis in cancer patients is the leading cause of death, and it is necessary to find a prognostic 
marker to detect the different types of cancer early in their progression phase. Based on these 
studies, NDRG2 is correlated with inhibition of invasion and metastasis and may function as a 
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prognostic marker in different cancer types [Zheng et al., 2010; Lorentzen et al., 2011]. High 
expression of NDRG2 have also been connected with better survival chances and smaller risk of 
developing metastases [Chu et al., 2011; Li et al., 2011; Oh et al., 2012; Zheng et al.,2010].  
1.4 Avoiding of immune destruction  
One of the hallmarks of cancer development is avoidance of immune destruction, and under 
normal cellular conditions the immune system is responsible for protection against foreign 
pathogens [De Visser et al., 2006; Hanahan & Weinberg, 2011]. All foreign pathogens, including 
tumor cells, express antigens and the immune system is introduced to these antigens by major 
histocompatibility complex (MHC) molecules on antigen-presenting cells (APCs) [Pardoll, 2012]. 
Tumor cells have developed different strategies to avoid the immune system, and the relationship 
between them is described by a theory called immunoediting [Dunn et al., 2002; Bhardwaj, 2007; 
Schreiber al., 2011].  
1.4.1 Immune system  
All living organisms have evolved 
strategies to protect themselves 
against pathogens, and these 
strategies are collectively referred 
to as the immune system 
[Hoffmann et al., 1999; Murphy et 
al., 2008; Waller et al., 2005]. The 
system consists of the immediate 
innate immune system and the highly specific adaptive immune system, and by collaboration of 
these two systems the immune system is able to recognize and eliminate invading pathogens 
[Palm & Medzhitov, 2009]. The system works through recognition, reaction, regulation, and 
memory functions, which differ between the innate immune system and the adaptive immune 
system [Medzhitov & Janeway, 1997; Cooper & Alder, 2006]. The innate immune system detects 
infections by recognition of unique molecular structures, and the adaptive immune system uses 
Figure 6 shows the different types of cells in the immune system [Dranoff, 2004] 
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highly specific receptors to recognize nearly any antigen and their clonal expression [Medzhitov & 
Janeway, 1997; Cooper & Alder, 2006]. Both systems are composed and react through several 
different cell types, see Figure 6 [Dranoff, 2004]. 
1.4.2 Innate immunity 
The innate immune system is the first defense against pathogens, and it consists of several cell 
types including the white blood cells. Besides B lymphocytes (B cells) and T lymphocytes (T cells), 
both dendritic cells (DCs) and macrophages are important for the interplay between the innate 
immune system and the adaptive immune system [Abbas et al., 2007]. All cell types mentioned in 
Table 2 express specific recognition receptors and become activated during an inflammatory 
response. After activation, the cells become effector cells, whose primary role is to combat 
detected pathogens [Janeway & Medzhitov, 2002]. 
 
Cell types Function Reaction  
Neutrophils The most important cell in the innate 
immunity. Acts on many different 
pathogens 
Early phagocytosis and killing of pathogens 
Dendritic cells 
(DCs) 
 Linked to both innate and adaptive 
immunity. Present antigens for T cells 
Release cytokines, when introduced to pathogens 
Macrophages  Present antigens for T cells  Efficient phagocytosis and killing pathogens, 
secretion of cytokines that stimulate inflammation  
Natural killer 
(NK) cells  
Recognize abnormal cells and kill them, 
e.g. tumor cells.  
Lysis of infected cells and activation of macrophages  
Table 2 shows the most important cell types of the innate immune system and further describe their function and reaction 
pattern [Abbas et al., 2007; Murphy et al., 2008; Wood, 2006; Clancy, 1998] 
The epithelial barrier and circulating plasma proteins have also been considered a part of the 
innate immunity [Janeway & Medzhitov, 2002; Abbas et al., 2007].  The epithelial barrier produces 
antibiotics, and together with lymphocytes it helps to prevent penetration into the host. 
Circulating plasma proteins are a varied group of proteins e.g. the proteins of the complement 
system, which are also able to recognize pathogens and serve as effector molecules [Abbas et al., 
2007].  
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1.4.3 Recognition of pathogens by the innate immune system  
The innate immunity uses special structures called pathogen-associated molecular patterns 
(PAMPs) to detect pathogens. These patterns are unique for each pathogen, and they are products 
of pathways that are unique for the microbe, which allows for discrimination between self and 
non-self molecules [Janeway & Medzhitov, 2002; Abbas et al., 2007; Medzhitov, 2007]. The innate 
immune system uses a variety of pattern recognition receptors (PRRs), which are expressed on the 
cell surface, in intracellular compartments, or in the circulating system, and the most well-known 
are Toll-like receptors (TLRs) [Janeway & Medzhitov, 1997]. When the PRRs are bound to the 
PAMPs, the PRRs become activated and induce one or two responses; activation of antimicrobial 
and proinflammatory functions in the cells and/or facilitating pathogen uptake into the cell. Some 
PRRs are soluble and ensure clearance of pathogens in blood and extracellular fluids [Abbas et al., 
2007]. As mentioned earlier, other mechanisms have evolved in the innate immune system to 
recognize pathogens, and these include the complement system, specialized receptors for NK 
cells, and other intracellular sensors [Hoebe et al., 2004].  The activation of the innate immune 
system is important for the development of the adaptive immune systems responses [Takeda & 
Akira, 2005]. 
1.4.4 The interplay between the innate immune system and the adaptive 
immune system  
Activation of the adaptive immune system requires two specific signals, where one is provided by 
the innate immune system, and the interplay between these two systems is therefore of highest 
importance in the recognition and elimination of pathogens [Kindt et al., 2007]. The adaptive 
immune system recognizes pathogens through antigens presented by antigen-presenting cells 
such as DCs and macrophages, which are part of the innate immune system [Hoebe et al., 2004; 
Lydyard et al., 2001; Akira et al., 2006]. T cells and B cells are a major part of the adaptive immune 
system, and they are also able to recognize antigens and produce appropriated responses. Besides 
antigen presentation, an additional signal is needed for full activation of T cells and B cells to 
ensure correct distinction between foreign antigens and self-antigens. This signal is provided by 
different soluble molecules released by the innate immune system, e.g. cytokines [Abbas et al., 
2007].  
 24 
1.4.5 Adaptive immunity 
All responses by the adaptive immune system are primarily produced by lymphocytes, including B 
cells and T cells, which are further described in a later section [Kindt et al., 2007; Werling et al., 
2003]. T cells and B cells become activated when they are presented to foreign antigens, which are 
only expressed when pathogens are present in the host. All antigens have their own unique 
molecular structure, and these structural variations are called the antigenic variation [Lydyard et 
al., 2001; Wood, 2006; Murphy et al., 2008]. Antigens are able to interact with antibodies 
produced by the host as a response against pathogens. Antibodies are glycoproteins grouped in 
five distinct classes, and they interact with antigens with a high specificity and affinity [Lydyard et 
al., 2001; Wood, 2006; Murphy et al., 2008].  Antigens are presented on the surface of APCs, and 
APCs are only able to present the antibodies through MHC glycoprotein molecules. The MHC 
molecules are encoded by large clusters of genes called MHC genes and are organized in three 
classes of molecules [Reche & Reinherz, 2003]. MHC genes are expressed by different cell types. 
MHC Class I molecules are expressed by almost every nucleated cell and assist in the presentation 
of antigens to T cytotoxic (Tc) cells. MHC Class II molecules are expressed primarily on APCs and 
present antigens to T helper (Th) cells. MHC Class III genes code for proteins e.g. in the 
complement system, immune receptors, TNF, and regulatory receptors [Trowsdale, 2001; Kindt et 
al., 2007]. When antigens are presented on APCs by MHC molecules, the adaptive immune system 
will be able to distinguish between self and foreign antigens and produce a proper response. After 
the antigen-antibody interaction occurs, the antigens are removed by specific antibody responses 
leading to phagocytosis of foreign cells [Kumagai & Tsumoto, 2001; Wood, 2006; Lydyard et al., 
2001]. 
1.4.6 B cell and T cell function and activation  
B cells and T cells are developed in the bone marrow and belong to the lymphocytes, which are 
the only cells in the body capable of recognize and distinguishing foreign antigens. Furthermore, 
they are responsible for the adaptive immune system’s characteristics, which include specificity 
and memory [Abbas et al., 2007]. Both classes of cells are described in Table 3.     
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Class Function Antigen presentation 
CD4+ T Helper (Th) 
lymphocytes  
B cell differentiation (Humoral immunity) 
Macrophage activation (cell-mediated immunity) 
Able to recognized antigens present 
by MHC class II complexes 
CD8+ T cytotoxic (Tc) 
lymphocytes 
Killing of cells infected by pathogens  
Killing of tumor cells 
Able to recognized antigens present 
by MHC class I complexes  
T Regulatory (Tregs) 
cells 
Suppress function of other T cells (regulation of 
immune responses, maintenance of self-
tolerance) 
 
B lymphocytes (B cells) Antibody production  (humoral immunity) Surface antibody 
Table 3 shows the most important cell types of the adaptive immunity, their function and antigen presentation [Abbas et al., 
2007; Murphy et al., 2008; Wood, 2006; Clancy, 1998] 
B cells are not fully developed, when they are released from the bone marrow, and they are called 
naïve B cells until they are activated. They become activated by antigen-antibody interactions 
through B cell receptors presenting membrane-bound antibodies. After the interaction, the 
proliferation and differentiation stages are completed, and the B cells become memory B cells or 
effector B cells also called plasma B cells. Memory B cells express the same membrane-bound 
antibodies as naïve B cells, whereas plasma B cells produce antibodies released to the 
environment as part of the humoral immunity [Kindt et al., 2007; Wood, 2006; Murphy et al., 
2008].      
The production of T cells also starts in the bone marrow, but unlike B cells, T cells migrate to the 
thymus in order to mature completely. Two types of T cells are produced, and both cell types 
express T cell receptors (TCRs), see Table 3. The two T cells types differ from each other by 
expressing different membrane glycoproteins on the surface. Th cells and Treg cells both express 
CD4 on their surface, but differ in surface markers and activation. Tc cells express CD8 on their 
surface. Most TCRs are only able to recognize antigens through MHC molecules [Kindt et al., 2007; 
Wood, 2006; Murphy et al., 2008].  
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1.4.7 The Adaptive immunity is able to respond in two different ways 
The adaptive immune system can react by using two different response mechanisms; humoral and 
cell-mediated response. The humoral immunity only detects extracellular antigens, whereas the 
cell-mediated immunity only detects intracellular pathogens, see Figure 7 [Kindt et al., 2007; 
Abbas et al., 2007]. Humoral immunity is performed by activated B cells, which bind antigens 
expressed by extracellular microbes through their receptors. Before the humoral response can be 
launched, Th cells have to present the extracellular antigens to the B cells, which then leads to 
activation and maturation of the B cells. The activated B cells mature into plasma B cells and 
memory B cells, where plasma B cells release antibodies against the extracellular pathogens and 
memory B cells recognize and remember the antigen specificity. The released antibodies interact 
with the antigens and facilitate the 
clearance of the pathogens [Kindt et al., 
2007; Murphy et al., 2008]. 
Cell-mediated immunity recognizes and 
eliminates intracellular pathogens and 
detects genetic modifications in cells, e.g. 
modifications seen in tumor cells [Lydyard 
et al., 2001; Kindt et al., 2007].  
For activation of T cells, two different 
signals are necessary provided by APCs 
and co-stimulatory molecules. TCRs can 
only bind to antigens presented by MHC 
class II molecules and the co-stimulatory 
molecules; B7 is expressed by APCs, which interact with CD28 on T cells [Chen et al., 1992; Guinan 
et al., 1994]. Proliferation of naïve T cells begins, when both signals are present, and the activated 
T cells become effector T cells, which include both Th cells and Tc cells. Memory T cells can be 
developed instead of effector T cells during the proliferation, and they have almost the same 
function as memory B cells, see Figure 7 [Lydyard et al., 2001; Kindt et al., 2007]. Activated Th cells 
are separated into two different subtypes, Th1 and Th2 cells, where Th1 cells are primarily 
Figure 7 shows the two types of adaptive immunity [Abbas et al., 
2007] 
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developed to fight against infections caused by intracellular bacteria [Kindt et al., 2007]. They 
trigger a phagocyte-mediated host response through the production of high levels of interferon 
gamma (IFN-γ) and tumor necrosis factor alpha (TNF-α).  Parasites and allergens activate Th2 cells 
and trigger a phagocyte-independent host response by producing cytokines such as IL-4, IL-5 and 
IL-6, which are all involved in B cell differentiation and maturation, thus indicating that Th2 cells 
are primary involved in humoral immunity [Romagnani, 1995; Lydyard et al., 2001].  
Many cytokines produced by Th cells are essential for activation of Tc cells, and naïve Tc cells are 
incapable of eliminating any target cells. Tc cells recognize antigens presented by MHC class I 
molecules expressed on all nucleated cells. Thereby, Tc cells are able to recognize and eliminate 
almost any cell expressing MHC class I molecules [Kindt et al., 2007]. Before Tc cells can be 
activated, they need three signals. Two of them are the same as mentioned for Th cells activation, 
and the third signal is induced by inflammatory cytokines [Curtsinger & Mescher, 2010].  
1.4.8 Cancer immunology  
One of the issues about tumor formation is how cancer cells are able to progress and avoid the 
immune system. The theory about immunosurveillance proposes that cells and tissues are 
monitored constantly, and thereby the immune system is able to recognize and eliminate 
precancer cells and nascent tumors [Hanahan & Weinberg, 2011]. Several studies support this 
theory. Experiments have shown increased tumor development and higher progression rate in 
mice that are genetically engineered for deficiency of various components of the immune system 
when compared to mice with an intact immune system. These observations were made in mice 
with engineered deficiencies in development or function of cytotoxic T cells, Th1 cells, or NK cells. 
Furthermore, mice with combined deficiencies in both T cells and NK cells were even more 
susceptible to cancer development [Bui & Schreiber, 2007; Finn, 2008; Vajdic & van Leeuwen, 
2009; Teng et al., 2008; Kim et al., 2007]. Over time several theories and hypotheses have 
attepted to answer the question of how tumor cells are still able to survive. The most recent 
theory is called immunoediting, which includes three essential phases; elimination, equilibrium, 
and escape [Kim et al., 2007].     
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1.4.9 Immunoediting: from immune surveillance to immune escape    
In 1909, Ehrlich proposed a theory on the role of the immune system in protection against cancer 
[Ehrlich, 1909]. This theory was later modified by Burnet and Thomas, who provided the theory 
about immunosurveillance, which has later been validated by findings of tumor-associated 
antigens in tumor transplantation models [Burnet, 1964 &Thomas, 1959]. It has now become clear 
that the immune system has three distinct roles in preventing cancer development, which include 
protection of the host against viral infections and virus-induced tumors, preventing establishment 
of an inflammatory environment to prevent production of inflammatory components, and 
elimination of nascent tumor cells [Schreiber et al., 2011]. In 2001, it became clear that the 
immune system was controlling both tumor quantity and quality, also termed immunogenicity 
[Shankaran et al., 2001; Dunn et al., 2002]. This was based on results of studies with 
immunocompetent mice (intact immune system) and immunodeficient mice (lack of immune 
components), which showed that tumors transplanted from immunocompetent mice into naïve 
wild type recipients were able to develop in the new host, whereas tumors received from 
immunodeficient mice were not able to continue to grow in the new host [Shankaran et al., 2001]. 
Furthermore, these results also revealed that tumors from immunocompetent mice were more 
immunogenic than those from immunodeficient mice, and they indicate that the immune system 
not only protects against tumor development, but also affects the immunogenicity in tumor cells 
[Schreiber et al., 2011]. These statements form the basis of the cancer immunoediting hypothesis, 
which brings us closer to a possible explanation of how tumor cells are able to survive and prevent 
immune responses, including three different phases; elimination, equilibrium, and escape [Dunn 
et al., 2002; Bhardwaj, 2007; Kim et al., 2007; Vesely et al., 2011; Dunn et al., 2004; Smyth et al., 
2006; Swann & Smyth, 2007].   
1.4.10 From elimination to escape  
The elimination of cancer cells is supported by antitumor immune responses, and experiments 
with infiltration of Tc cells and NK cells in the tumor have shown better prognosis for the survival 
[Bindea et al., 2010; Ferrone & Dranoff, 2010; Nelson, 2008]. It has been observed that 
immunosuppressed organ transplant recipients can develop cancer after transplantation of a 
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tumor-free organ, which indicates that an intact immune system is important to hold the cancer 
cells in check [Strauss & Thomas, 2010].      
In the phase called equilibrium, the cancer cells are living in equilibrium with the immune system 
of the host. Increased sculpting of cancer cells leads to production of cells with resistance to 
immune effector cells, and through immune selection cancer cells with reduced immunogenicity 
are able to survive the immune responses [Kim et al. 2007]. Tumor cells with reduced 
immunogenicity are more capable of surviving in hosts with an intact immune system, and several 
studies in mice with a range of deficiencies have indicated different degrees of immune selection 
pressure [Kim et al., 2007]. The tumor-host equilibrium can be explained by the possibility that 
highly immunogenic cancer cells are able to avoid the immune system through disabling of 
important immune components involved in elimination of cancer cells [Shields et al., 2010; 
Hanahan & Weinberg, 2011].     
The phase of cancer cell escape can be described as the tumors’ ability to avoid and prevent 
immune recognition. Several tumor-derived soluble factors are able to induce different 
mechanisms, all important in escape from immune attacks [Kim et al., 2007]. This phase includes 
multiple steps and strategies, such as loss of antigenic presentation, tumor antigens, sensitivity 
against immune-effector molecules, and induction of Treg cells, which are all further described in 
the section below. 
1.4.11 Cancer cells’ most common strategies to avoid the immunity  
All strategies presented in this section are the most well-known and documented, and they 
represent many aspect of the immune system.  
1.4.11.1 NK cells and the NKG2D receptor  
Under normal conditions NK cells’ ability to kill directly is inhibited by the presence of MHC class I 
molecules. Inhibition of NK cells happens when MHC class I molecules bind to NK cells through a 
receptor called killer inhibitory receptor (KIR) [Cerwenka & Lanier, 2001]. Without the expression 
of MHC class I molecules on the cell surface, NK cells are activated to kill the cell [Weinberg, 2013]. 
NK cells recognize tumor cells through different NK receptors, NKp46, NKp50 and NKG2D, where 
the NKG2D receptors are the most well known [Gasse & Raulet, 2006]. As a result of genetic 
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damage, viral infection, and neoplastic transformation many cells express stress signal proteins, 
and these can be detected by NK cells through the NKG2D receptors [Bui & Schreiber, 2007; 
Weinberg, 2013]. Interaction between the NKG2D receptor and the stress signal proteins leads to 
a release of IFN-γ, which consequently elicits several distinct responses. Many components of the 
immune system are recruited by release of IFN-γ including macrophages, which are able to kill 
either directly or indirectly through APCs. Additionally, IFN-γ also increases the expression of MHC 
class I molecules on tumor cells leading to expression of tumor antigens and further adaptive 
responses [Weinberg, 2013]. Under normal conditions tumor cells would be expected to release 
stress signal proteins as a consequence of the neoplastic transformation leading to activation of 
the NKG2D receptor and an up-regulation of stress signal proteins, but a down-regulation of these 
stress signal proteins is observed in tumor cells instead [Bui & Schreiber, 2007; Gasser & Raulet, 
2006]. This is supported by experiments in mice capable of expressing NKG2D, which have shown 
that tumor cells suppress the expression of the Rae1 stress antigen in order to avoid NK cell attack 
[Weinberg, 2013].    
1.4.11.2 MHC molecules 
NK cells and Tc cells use the same killing mechanism by introducing a protease to target the cell 
and induce apoptosis. Tumor cells are able to avoid the attack from Tc cells by increasing the level 
of inhibitor-of-apoptosis proteins [Krajewska et al., 2003]. Normally Tc cells recognize tumor cells 
through tumor antigens presented by MHC class I molecules on APCs, but tumor cells have also 
shown ability to down-regulate the expression of MHC class I molecules [Finn, 2008; Houghton & 
Guevara, 2004; Hicklin et al., 1999; Garrido et al., 1997]. Down-regulation of MHC class I molecules 
makes the tumor cells less antigenic, and thereby they avoid immune responses because of the 
missing detection of tumor antigens. The expression of antigens is inhibited by promoter 
methylation of antigen-coding genes, which makes the tumor cells invisible to effector immune 
cells [Bicknell et al., 1994]. The migration of MHC class I molecules from the endoplasmic 
reticulum (ER) to the cell surface depend on beta-2 microglobulin (B2m) proteins. Synthesis of 
B2m proteins is inhibited by some tumor cells and the transport of MHC class I molecules is 
prevented, which leads to repressed expression of antigens [Weinberg, 2013]. Another mechanism 
seen especially in highly invasive and metastatic tumors is inhibition of the transcription of MHC 
class I genes, which leads to reduced mRNA and prevents further synthesis of MHC class I 
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molecules [Weinberg, 2013]. In some cases, tumor antigens are essential for neoplastic 
proliferation, and a down-regulation of the MHC class I molecules will lead to activation of NK cells 
and elimination of the tumor cells. Six types of MHC class I molecules have been classified and 
some tumor cells are able to selectively suppress expression of only one of these molecules, which 
are normally expressed concomitantly by cells throughout the body. This may block the 
presentation of tumor antigens and thereby prevent attack by Tc cells and NK cells [Weinberg, 
2013].     
1.4.11.3 Treg cells  
A population of T cells known to express high levels of CD25 and other proteins are called Treg 
cells, and under normal conditions they are produced to suppress autoreactive T cells through 
contact-dependent mechanisms [Bhardwaj, 2007; Curiel, 2007]. Improved immune-mediated 
tumor rejection and tumor antigen-specific immunity have been found in studies with mice lacking 
Treg cells [Curiel, 2007]. Two different types of Treg cells have been found including natural and 
adaptive Treg cells [Curiel, 2007].  Natural Treg cells are produced in the thymus to prevent 
autoimmunity, whereas adaptive Treg cells are produced under inflammatory conditions such as 
infections or cancer [Curiel, 2007]. Adaptive Treg cells suppress effector T cells through direct 
contact and production of immune-suppressive cytokines, IL-10, and growth factor beta (TGF-β) 
[Curiel, 2007; Zou, 2006; Bhardwaj, 2007; De Visser et al., 2006; Finn, 2008]. Tumors recruit 
adaptive Treg cells by the chemokine CCL22, and they infiltrate the tumor microenvironment by 
interaction with adaptive Treg receptors called CCR4. Located in the middle of the tumor they 
inhibit the action of effector T cells [Weinberg, 2013]. The production of TGF-β in mice with 
tumors has shown conversion of antitumor effector T cells into Treg cells [Woo et al., 2001 & Liu et 
al., 2007]. Furthermore, TGF-β and tumor cells have been found to induce the differentiation of 
Treg cells [Curiel, 2007].  
1.4.11.4 Transforming growth factor beta (TGF-β) 
Tumor cells produce different immunosuppressive products, such as TGF-β, Fas ligand (FasL), and 
indolamine-2,3-dioxygenase (IDO), which are all produced to prevent or decrease immune 
responses [Finn, 2008; Elgert et al., 1998; Chouaib et al., 1997]. TGF-β is a cytokine involved in 
proliferation, activation, differentiation, and apoptosis of innate and adaptive immune cells and 
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functions by inhibition of antitumor immune responses [Igney & Krammer, 2002; Siegel & 
Massagué, 2003]. TGF-β is able to reduce the presentation of antigens through APCs by inducing 
apoptosis and thereby decreasing the number of APCs [Weinberg, 2013]. Furthermore, TGF-β has 
an immunosuppressive cytostatic effect on T cells, and NK cells, and prevents maturation of DCs 
by inhibition of MHC class II molecules expression [Weinberg, 2013; Siegel & Massagué, 2003]. 
1.4.11.5 Indolamine-2-3-dioxygenase (IDO) 
Tumor cells are able to develop an immune-suppressive enzyme called IDO [Uyttenhove et al., 
2003 & Muller & Prendergast, 2007]. Earlier, the enzyme has been connected with tolerance 
between mother and fetus, but later it has been found to regulate auto-immunity by T cell 
activation [Munn et al., 2002]. IDO is up regulated in both tumor cells and DCs, and its function is 
dependent on activation signals from APCs [Bhardwaj, 2007; Prendergast, 2008]. Most IDO is 
found in the tryptophan catabolism function as a rate-limiting enzyme, whereby it induces a fall in 
tryptophan level and has a negative consequence for T cell proliferation [Bhardwaj, 2007; Finn, 
2008]. Studies with inhibitors of IDO in mice have shown an induction of immunity [Finn, 2008].  
1.4.11.6 Fas receptor and Fas ligand  
Fas receptor (FasR) and FasL molecules play important roles in immune escape and tolerance 
[O’Connell et al., 1996; Zhang et al., 2007]. FasL is able to induce apoptosis in immune cells leading 
to limited immune responses [Nguyen & Rusell, 2001; O’Connell et al., 1996]. Activation of 
apoptosis happens when FasL interact with FasR, but tumor cells are able to develop resistance 
against FasL-mediated mechanisms by releasing soluble FasL. The attention is then removed from 
the tumor cells over to the different lymphocytes, where FasR will interact with the soluble FasL 
[Connell et al., 1996; Weinberg, 2013]. Furthermore, tumor cells can attack Fas-sensitive tumor-
infiltrating lymphocytes (TILs) by increasing the level of FasL, which leads to tumor cell immunity 
and cancer progression [Lin et al., 2001; Zhang et al., 2007].  
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1.5 Tumor-promoting inflammation 
A second enabling characteristic is tumor-promoting inflammation, and this involves the balance 
between the immune system and the tumor microenvironment. Chronic inflammation has been 
associated with cancer progression and inadequate pathogen eradication, prolonged 
inflammatory signaling, and defects in anti-inflammatory mechanisms [Han & Ulevitch, 2005]. The 
tumors are infiltrated with cells from both the innate and adaptive immunity, and the 
inflammation response contributes with bioactive molecules to the tumor microenvironment. 
These bioactive molecules, including growth factors, survival factors and extracellular matrix-
modifying enzymes, can all lead to proliferation, continued survival, angiogenesis, invasion, and 
metastasis [Hanahan & Weinberg, 2011; DeNardo et al., 2010; Grivennikov et al., 2010; Qian & 
Pollard, 2010; Karnoub & Weinberg, 2006-2007].  The network of the tumor microenvironment 
includes inflammatory cytokines, growth factors, and chemokines produced by tumor cells or 
tumor-associated leukocytes and platelets [Balkwill & Mantovani, 2001; Grivennikov & Karin, 
2010; Hsu & Chung, 2006; Lin & Karin, 2007].  
1.5.1 Inflammation and cancer 
Since the 19th century inflammatory cells have been observed within tumors, and tumors often 
occur at sites of chronic inflammation, which provides the first indication of a possible link 
between inflammation and cancer [Schetter et al., 2010; Grivennikov et al., 2010; Balkwill & 
Mantovani, 2001]. Epidemiological studies now support these findings and suggest that up to 25 % 
of cancer cases are related to inflammation, and that 15-25 % of all deaths from cancer are linked 
to infections and inflammation [Aggarwal et al., 2009; Perwez Hussain & Harris, 2007; Balkwill & 
Mantovani, 2001]. Several chronic inflammatory diseases have been connected with increased risk 
of cancer development including Crohn’s disease, ulcerative colitis, chronic pancreatitis, and 
chronic bronchitis [Ekbom et al., 1990; Gillen et al., 1994; Ekbom et al., 1993; Wu et al., 1995; 
Mayne et al., 1999]. Furthermore, chronic inflammation caused by microbial or parasitic infections 
is involved in development of cancer by viral hepatitis B and C, Helicobacter pylori, and parasitic 
worms, which all lead to chronic inflammation and promotion of several cancer types [Schetter et 
al., 2010; Tsukuma et al., 1993; Parsonnet et al., 1991; Grivennikov et al., 2010].  
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  Studies have shown that 90 % of all cancers are associated with somatic mutations and 
environmental factors, and many of these factors are related to chronic inflammation 
[Grivennikov et al., 2010]. Acute inflammation often occurs as a response to microbial infection 
and tissue damage, however whether chronic inflammation is triggered by microbial infections, 
autoimmune disease, viral infections, exposure to allergens, toxic chemicals, obesity, and 
inflammation is still unknown [Mantovani et al., 2008; Schetter et al., 2010]. Tissue homeostasis is 
monitored by the immune system, and tissue damage or infections interrupt the balance and lead 
to an immune response. Sometimes an imbalance of the response provided by the innate immune 
system leads to constant activation of the immune system and subsequently to chronic 
inflammation [De Visser et al., 2006]. Cells exposed frequently to chronic inflammation will 
undergo oncogenic transformation, and the causes of this are many, e.g. induction of genomic 
instability, increased angiogenesis, epigenetic altering, and increased proliferation. Furthermore, 
inflammation is able to change the gene expression of oncogenes and tumor suppressor genes in 
order to promote neoplastic transformation [Schetter et al., 2010]. Chronic inflammation can 
provide the tumor environment with a supply of inflammatory mediators, which include growth 
factors, survival factors, proangiogenic factors, extracellular matrix-modifying enzymes, and 
inductive signals, all involved in either proliferation, apoptosis, angiogenesis, invasion, or 
metastasis [DeNardo et al., 2010; Grivennikov et al., 2010; Qian & Pollard, 2010; Karnoub & 
Weinberg, 2006-2007]. The outcome of an inflammatory immune response depends on the 
balance between proinflammatory and anti-inflammatory mediators of the adaptive and innate 
immune system, and inappropriate responses of the immune system can affect this balance, see 
Figure 8  [Ben-Baruch, 2006; Kim et al., 2006; Schetter et al., 2010].     
 
Figure 8 shows the importance of the overall balance between proinflammatory and anti-inflammatory mediators [Schetter et 
al., 2010]  
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The connection between cancer and inflammation 
can be explained by the intrinsic and extrinsic 
inflammation pathways, see Figure 9  [Mantovani et 
al., 2008; Schetter et al., 2010]. The difference 
between the two pathways is the way they are 
activated. The intrinsic pathways are primarily 
activated by genetic events including genetic 
alterations of oncogenes and tumor suppressor 
genes leading to cancer, whereas the extrinsic 
pathways involved in cancer are caused by infection 
and chronic inflammation [Mantovani et al., 2008; 
Schetter et al., 2010]. The two pathways only differ 
in their activation and cause of cancer promotion, 
but both of them result in activation of 
transcription factors such as NF-κB, STAT3 and 
HIF1α in both tumor cells and immune cells [Karin, 
2006; Yu et al., 2007]. When the transcription 
factors are activated, they ensure production of 
prostaglandins, chemokines, and cytokines by the 
tumor cells, where the cytokines are signaling 
molecules involved in many cellular functions especially 
in inflammation and immune responses [Schetter et al., 2010; Mantovani et al., 2008]. Cytokines 
are classified as either pro-inflammatory or anti-inflammatory mediators, and they are important 
for the balance between promotion and suppression of cancer mentioned earlier, but also for the 
recruitment and activation of leukocytes [Schetter et al., 2010]. Thereby the same transcription 
factors are activated again, but this time in both inflammatory cells and tumor cells, which leads to 
production of more inflammatory mediators, and the environment for cancer development is 
generated [Mantovani et al., 2008]. One of the inflammatory mediators is the cytokine interleukin 
6 (IL-6), which is important in transition from acute inflammation to chronic inflammation and 
triggers the activation of the transcription factor STAT3 [Erreni et al., 2011].              
Figure 9 shows the intrinsic and extrinsic inflammation 
pathways that connect cancer and inflammation 
[Mantovani et al., 2008] 
 36 
1.5.2 Function of IL-6 and its role in cancer  
The family of IL-6 cytokines consists of IL-6, leukemia inhibitory factor, oncostatin M, 
cardiotrophin-1, ciliary neurotrophic factor, and cardiotrophin-like cytokine [Taga & Kishimoto, 
1997; Derouet et al., 2004]. Common for all is the ability to activate the signal transducing 
receptor protein Gp130, and thereby activation of target genes involved in differentiation, 
survival, apoptosis, and proliferation [Heinrich, 2003].  
IL-6 is a multifunctional cytokine with functions in both immune and non-immune cells produced 
by lymphoid and non-lymphoid cells such as T cells, B cells, monocytes, fibroblasts, endothelial 
cells, and several tumor cells [Heinrich, 2003; Becker et al., 2004; Grivennikov & Karin, 2008 
Kishimoto, 1989]. IL-6 has both pro- and anti-inflammatory properties and is important for 
immune responses, cell survival, apoptosis, proliferation, and production of acute phase proteins 
[Heinrich, 2003 & Kishimoto, 1989]. The expression of IL-6 is regulated both negatively and 
positively by different cytokines. TNF-α and IL-1 are able to increase the production of IL-6, 
whereas glucocorticoids affect the production of IL-6 negatively [Kishimoto, 1989].  
The group of IL-6 receptors is arranged into two subunits of receptors, non-signaling α-receptors 
(IL-6Rα, IL-11Rα and CNTFRα) and signal transduction receptors (gp130, LIFR and OSMR) [Heinrich, 
2003]. In order to establish the complex, IL-6 interacts with the α-receptor (IL-6Rα) integrated in 
the cell membrane. The IL-6/ IL-6Rα complex then interacts with the gp130 glycoprotein on the 
cell surface thus forming an activating receptor unit, which leads to activation of the STAT 
pathway. Gp130 glycoproteins are expressed on almost every cell in the organisms, whereas the 
expression of IL-6Rα is restricted and tightly regulated leading to the degree of cytokine sensitivity 
in the cell [Grivennikov & Karin, 2008; Heinrich et al., 2003].   
Cells missing the membrane-bound receptor can be activated by trans-signaling through the 
soluble IL-6 receptor (sIL-6R). Together, sIL6R and IL-6 form a complex called the IL-6/sIL-6R 
complex. This interaction shows exactly the same activation of the JAK/STAT pathway as seen 
when interacting with IL-6Rα units [Lin & Karin, 2007; Becker et al., 2004]. When the JAK/STAT 
pathway is activated, JAK1 handles the phosphorylation of STAT proteins including STAT1 and 
STAT3, see Figure 10. Nuclear translocation and activation of specific target genes happen through 
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phosphorylation dimerization, and target genes are primarily involved in cell cycle progression and 
suppression of apoptosis. STAT3 proteins are predominant in IL-6 signaling transduction and 
further involved in malign cell proliferation and survival. STAT1 has been shown to inhibit the 
growth of tumor cells, and studies in lung cancer cells have shown that knockdown and inhibition 
of STAT3’s phosphorylation lead to delayed cell growth [Lin & Karin, 2007]. Moreover, a role as a 
pro-tumor agent has been suggested for IL-6 supported by poor prognosis related to significantly 
elevated levels of IL-6 found in lung and breast cancer 
patients [Grivennikov & Karin, 2008].  
 In addition to activation of the JAK/STAT pathway, IL-6 
can work directly with some immune cells in response 
to pathogens. Further studies have shown IL-6 
involvement in the final step in differentiation of B cells 
and stimulation of B cells to become plasma B cells 
[Abbas et al., 2007]. Kishimoto has suggested a 
potential role for IL-6 as a factor for T cell activation and 
proliferation, based on the fact that resting T cells 
express IL-6Rα [Kishimoto, 1989]. Thereby IL-6 is an 
important part of the immune system and the activation 
of the JAK/STAT pathway.  
1.5.3 Interleukin 6 and NDRG2  
Immune responses in the tumor microenvironment can promote or inhibit cancer progression, 
and the STAT proteins have a central role in determining the response outcome [Yu et al., 2009]. 
STAT3 and NF-kB function as nuclear transcription factors for genes involved in tumor 
proliferation, survival, angiogenesis, and invasion, and NF-kB further targets genes coding for IL-6, 
which functions as a STAT3 activator. STAT3 induces the expression of cytokines, growth factors, 
and angiogenesis factors leading to activation of theirs associated receptors, which result in a 
reactivation of STAT3, including IL-6 and IL-10 [Naugler & Karin, 2007; Yu et al., 2009]. Thereby a 
feed-forward loop is created between tumor cells and immune cells in the tumor 
microenvironment, and the persistent activation of STAT3 promotes tumor-inflammation and 
Figure 10 shows JAK/STAT pathway [Shuai & Liu, 
2003] 
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inhibits anti-tumor immunity [Yu et al., 2009]. IL-6 and IL-10 are both key activators of STAT3, and 
NDRG2 expression has been found to induce SOCS1, which negatively regulates STAT3 activation 
in breast cancer cells [Park et al., 2007]. Furthermore, NDRG2 expression has been observed to 
modulate SOCS3 and STAT3 activity, which may lead to inhibition of IL-10 [Lee et al., 2010]. IL-6 
and IL-10 are strongly connected, and therefore it would be interesting to see if a connection 
between NDRG2 expression and IL-6 levels exists.  
1.6 Short summary  
Various mechanisms have been connected to tumorigenesis including emerging hallmarks and 
enabling characteristics, which describe the relationship between the immune system and cancer 
and genomic changes involved in tumorigenesis [Hanahan & Weinberg, 2011]. Silencing of tumor 
suppressor genes is an important mechanism of tumorigenesis and can lead to inhibition of tumor 
suppressor genes’ normal function in suppression of cancer development [Hanahan & Weinberg, 
2011]. NDRG2 has been suggested as a potential tumor suppressor candidate, and the observation 
of down-regulation of NDRG2 in several cancer types supports this statement [Chu et al., 2011; Hu 
et al., 2004; Lee et al., 2008; Lorentzen et al., 2007; Piepoli et al., 2009; Lorentzen et al., 2011; 
Zhao et al., 2008; Ma et al., 2008; Wang et al., 2012]. Under normal cellular conditions, the 
immune system is responsible for protection against foreign pathogens including tumor cells [De 
Visser et al., 2006; Hanahan & Weinberg, 2011]. Furthermore, the responses of the immune 
system against inflammation and chronic inflammation have been associated with cancer 
development. The oncogenic transformation of tumor cells exposed to frequent chronic 
inflammation has been connected with epigenetic alterations and changed expression of tumor 
suppressor genes [Schetter et al., 2010]. Additionally, the tumor environment is supplied with 
inflammatory mediators including cytokines as a result of immune responses and chronic 
inflammation [DeNardo et al., 2010; Grivennikov et al., 2010; Qian & Pollard, 2010; Karnoub & 
Weinberg, 2006-2007]. An important cytokine is IL-6, which has been connected with chronic 
inflammation through its ability to activate STAT3, and persistent activation of STAT3 leads to 
inhibition of anti-tumor immunity [Yu et al., 2009]. NDRG2 expression has been reported to induce 
SOCS1 expression leading to down-regulation of STAT3 in breast cancer, therefore it would be 
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interesting to study a possible connection between NDRG2 expression and IL-6 levels in colon 
cancer cells [Lee et al., 2010]. 
2. The aim of the Master’s thesis   
The aims of this Master’s thesis are to study the influence that IL-6 and NDRG2 may have on colon 
cancer cells, and to study the impact that IL-6 may have on colon cancer cells proliferation with 
and without the expression of NDRG2 
Experimental description: 
- To use colon cancer cell lines to analyze the expression level of NDRG2 on both mRNA and 
protein level  
- To treat colon cancer cell lines with IL-6 and then analyze the expression of NDRG2 on 
mRNA level 
- To establish stable cell lines expressing NDRG2 
- To analyze if the expression of NDRG2 affects the growth rates of colon cancer cells  
- To analyze if colon cancer cells expressing NDRG2 may have different growth rates 
compared to cells without the expression of NDRG2 
- To analyze if transfected colon cancer cells expressing NDRG2 have different growth rates 
when treated with IL-6 
To perform the above-mentioned analyses, the methods and techniques described in the next 
section were used.  
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3. Materials & Methods  
The sections provide a short introduction to the theory behind the methods used, followed by a 
description of the particular use in this thesis. The experimental design is described briefly to give 
a better understanding of the process.  
3.1 Experimental Design  
In the present study, the expression of NDRG2 and the growth of colon cancer cells were 
examined under various conditions. The mRNA and protein expression of NDRG2 in the cell lines 
were examined by reverse transcription quantitative polymerase chain reaction (RT-qPCR) and 
western blotting.  The growth rate of the cell line was examined by growth assays.   
The conducted experiments are categorized into two groups and investigate different aspects of 
NDRG2 and the presence of IL-6, see Figure 11. 
 
Figure 11 shows a schematic overview of the two groups of experiments conducted through this master thesis  
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3.2 Cells Culture - growth, harvesting, and treatment  
All cell experiments were conducted with colon cancer cell lines SW480 and HCT116. The colon 
cancer cells lines SW480 and HCT116 were originally isolated from an adenocarcinoma and a 
colorectal carcinoma. The cells were cultured in T25 or T75 culture flasks supplied with McCoy’s 
5A medium (Sigma-aldrich, #M9309), 10% fetal bovine serum (Sigma-aldrich, #F0804), and 1% 
Penicillin-streptomycin (Sigma-aldrich, #P0781) to provide nutrition and avoid infections. To 
ensure optimal growth conditions, the cells were incubated at 37°C with 5% CO2 in a humidified 
atmosphere. 
The cells were passaged twice a week to ensure space for continued growth, and the frequency 
was based on the individual growth rate for the cell lines. The splitting procedure was as follows: 
wash with 10 ml PBS (Lonza, #BE17-512F) twice to remove the rest of the medium followed by 
trypsinization with 2 ml Trypsin 1X (Sigma-aldrich, #T3924) to loosen the cells from the bottom of 
the flasks. The cells were resuspended in 8 ml McCoy’s 5A medium to separate the cells 
completely, and around 1.5-2 ml cell suspension was kept for further culture.  
The rest of the cell suspension was used for isolation of RNA, DNA and protein. The cell suspension 
was transferred to a 15 ml tube and spun down for five minutes at 1500 rpm to isolate the cells. 
The supernatant was removed and the cells were resuspended in 3 ml PBS to remove any 
remaining medium. 1 ml of the cell suspension was transferred to three 1.5 ml eppendorf tubes 
and spun down for five minutes at 1500 rpm to isolate the washed cells. After removing the 
supernatant the pellets were stored at -80 °C.  
3.2.1 Treatment of Cells  
Cancer cell lines HCT116 and SW480 were treated with recombinant human IL-6 (Sigma-Aldrich, 
#H7416) in order to analyze the effect that different IL-6 levels may have on colon cancer cell lines 
and the expression of NDRG2.  
The treatment efficiency was first tested with different concentration and over a time period of 72 
hours, in order to find the most efficient concentration and time. Hsu & Chung have tested 
different concentrations for IL-6 treatment of colon cancer cells and based on their results the 
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following concentrations (10 ρM, 50 ρM and 10.000 ρM) were chosen for this study [Hsu & Chung, 
2006]. The cells were plated at a density of 1 x 105 cells per well in 24-well plates for 24 hours, and 
medium was changed before initiation of IL-6 treatment.  All samples were handled in duplicates 
or triplicates and treated with the following concentrations: 10 ρM, 50 ρM and 10.000 ρM over 
distinct time periods of 24, 48, and 72 Hours. Hereafter, the cells were harvested for further 
analysis. See Figure 12 for further information on the following procedure.  
 
Figure 12 shows the whole procedure for the treated cells 
When the most efficient concentration was found, the colon cancer cell line SW480 was treated 
with IL-6 to analyze if the cytokine had an impact on the growth rate of SW480 cells with and 
without expression of NDRG2. Only SW480 cells were used for treatment, because of the fact that 
the HCT116 cells do not express NDRG2 protein. Cells were plated at a density of 1 x 104 cells per 
well in 24-well plate for 24 hours, and the medium was changes before the treatment of IL-6 
(10,000 ρM) was started. All samples were handled in duplicates and treated over a time period of 
24, 96, and 168 hours.  
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3.3 Quantification of NDRG2 mRNA level 
The methods used to analyze the level of NDRG2 mRNA are described in the following section. 
These include RNA extraction, cDNA synthesis, and qRT-PCR.  
3.3.1 RNA extraction   
Before initiation of RNA extraction, all materials used were cleaned 
with RNaseZap (Sigma-aldrich, #R2020). RNA extraction includes the 
steps: homogenization, extraction, precipitation, and solubilization, 
see Figure 13: 
1. The cells were disrupted to separate RNA from the cells   
2. The homogenate was separated in an organic and an aqueous 
phase. RNA is found in the aqueous phase  
3. RNA was precipitated and the isolation of RNA was completed 
after the wash steps  
4. RNA was stored in Rnase-free water at -80°C until use 
Throughout the whole procedure, the pellet must stay on ice. The pellet was resuspended in 1 ml 
TRI reagent® solution (Ambion, #AM9738) and incubated at room temperature (RT) for five 
minutes. TRI reagent® solution contains phenol and guanidine thiocyanate, which inhibit the 
Rnase activity. The isolation of RNA from the cells is performed by centrifugation at 12000 x g, 4 °C 
for 15 minutes, and hereafter the supernatant was transferred to new tubes and work continued 
with these tubes.  
To separate RNA and waste, 100 μL of Chloroform (100%) was added to the supernatant and the 
tubes were vortexed shortly. The tubes were then incubated at RT for 10 minutes to ensure the 
phase division, and the tubes were then centrifuged at 12,000 x g, 4°C for 15 minutes to enable 
transfer of the RNA-containing phase to new tubes. Then 500 μL Isoprophanol (100%) was added 
and the samples were vortexed shortly. Samples were incubated at RT for 5 minutes followed by 
centrifugation at 12,000 x g, 4 °C for 20 minutes. Supernatants were discarded.  
Figure 13 shows the RNA 
extraction in steps [Ambion, 
2014] 
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Pellets were washed with 1 ml Ethanol 75% and centrifuged at 12000 x g, 4 °C for 20 minutes. The 
ethanol was gently removed, and the tubes were air-dried for maximum 10 minutes. The samples 
were then resolved in 50 μL of Rnase-free water and vortexed shortly, and the concentration of 
RNA was measured at 260 nm on the NanoDrop® spectrophotometer ND-1000. Pellets were 
stored at -80 °C or used immediately.  
3.3.2 cDNA synthesis   
By cDNA synthesis double stranded cDNA was 
produced and used downstream for quantification 
of mRNA levels of specific genes by qRT-PCR. 
Random primers annealed to all RNA sequences, 
and reverse transcriptase performed the synthesis 
of cDNA. Hydrolysis of RNA strands happen when 
the synthesis of cDNA is completed and the cDNA is 
now ready to use. See Figure 14.  
For cDNA synthesis, High capacity cDNA reverse 
transcription kit (Applied Biosystems, #4368814) 
was used, and the total volume of the mastermix for 
each reaction was 10 μL. The mastermix was 
prepared as follows: 2.0 μL 10X Reverse 
transcriptase buffer, 0.8 μL 25X dNTP mix (100 mM), 
2.0 μL 10X Reverse transcriptase Random Primers, 
1.0 μL MultiScribe™ reverse transcriptase and 4.2 μL nuclease-free water. Then, the mastermix 
was gently mixed and kept on ice until use to avoid activation of the reverse transcriptase.    
In preparation, the RNA samples were diluted to a concentration of 100 ng/μL in order to ensure 
an equal amount of RNA in all cDNA samples. 10 μL mastermix was transferred to 0.2 ml PCR tubes 
with 10 μL of diluted RNA and mixed to resolve the RNA in the mastermix.  
The thermal cycler was set to run at 25 °C for 10 minutes, 37 °C for 120 minutes, 85 °C for 5 sec 
and paused at 4 °C. The cDNA was stored at -20 °C.    
Figure 14 shows the cDNA synthesis step by step 
[Addison Wesley Longman, 1999] 
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To minimize the risk of contamination and to ensure that only the desired RNA was in the samples, 
two different cDNA control reactions were performed; one without RNA and one without 
MultiScribe™ reverse transcriptase.  
3.3.3 Quantitative real time polymerase chain reaction (qRT-PCR) 
Expression of mRNA of a preferred gene was measured by use of qRT-PCR, which is a procedure 
including several steps, see Figure 15:   
1. By denaturation at 95°C, double stranded DNA was separated.  
2. By primer annealing, forward and reverse primers were attached to each of the DNA 
strands at varied temperatures depending on the specific primer set.  
3. Extension was performed by DNA polymerase enzyme at 72°C. 
In this study the SYBR Green technique was used, which is a commonly used fluorescent DNA 
binding dye. Through binding to all double-stranded DNA, the increase in fluorescence can be 
measured through the cycle and is equal to the amount of DNA amplified over time.  
 
Figure 15 shows the different steps in the qRT-PCR procedure [Lu et al., 2011 (modified)]  
For qPCR, Quantitech® SYBR® Green PCR kit (Quigen, #204141) was used, and for each reaction 
the mastermix contained; 5 μL 2X Quantitech SYBR Green PCR mastermix, 0.5 μL (10 ρmol/μL) 
forward primer, 0.5 μL (10 ρmol/μL) reverse primer, and 3 μL nuclease-free water. Each reaction 
consisted of 1 μL cDNA and 9 μL mastermix, giving a total volume of 10 μL. Primer sequences and 
annealing temperatures can be seen in  
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Table 4 shows primer sequences and annealing temperatures (Tm) for quantitative Real Time Reverse Transcriptase 
Polymerase Chain Reaction (qRT-PCR)  
 
Table 4 shows primer sequences and annealing temperatures (Tm) for quantitative Real Time Reverse Transcriptase 
Polymerase Chain Reaction (qRT-PCR) 
 
The program at the thermo cycler was as follows; 95°C for 15 minutes, 95°C for 15 sec, annealing 
temperature (varied with primers) for 30 sec, and lastly 72°C for 30 sec, repeated for 40 cycles.   
3.3.4 Standard curve 
To assess the qPCR reaction, the efficiency of the primers is important, and by use of standard 
curves it is possible to optimize the qPCR. A template known to express the gene of interest was 
diluted at different concentrations to constitute a dilution series. The standard curve gives a linear 
regression formula, which can be used to determine the reaction efficiency. The optimal slope of 
the standard curve has a correlation coefficient (R2) of 0.999, but an R2 value greater than 0.98 is 
ok for an optimized PCR reaction. The slope of the standard curve can be analyzed and reaction 
efficiency can be evaluated over a range of different concentrations. Normal human liver cDNA 
(BD biosciences, #636742) was used for the standard curve for NDRG2 expression and normal 
human heart cDNA (BD biosciences, #636742) was used for RPLP0. The standard curve for MCL-1 
was prepared from human colon cancer cell line HCT116.  
Gene Forward Primer 5’  3’ Reverse Primer 3’  5’ Tm (°C) 
NDRG2 GCTACAACAACCGCCGAGAC ACAGGCGAGTCATGCAGGAT 55 
RPLP0 GCTTCCTGGAGGGTGTCC GGACTCGTTTGTACCCGTTG 52 
MCL-1 TAAGGACAAAACGGACTGG CCTCTTGCCACTTGCTTTTC 60 
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3.4 Detection of NDRG2 protein expression  
Methods to detect NDRG2 protein are described in the following sections. These include 
transfection, whole cell protein extraction, and Western blotting. The NDRG2 protein levels were 
investigated in the cancer cell lines HCT116 and SW480. Furthermore, these cells were transfected 
with three different plasmids, pCMV-EGFP, pcDNA6V5-HIS-A-EGFP and pcDNA6-NDRG2L-V5, see 
appendix II. After the transfection the NDRG2 protein level was investigated again. All further 
information on the antibodies and solutions used in the study can be found in Appendix I.  
3.4.1 Transfection  
Specific DNA is transfected into cells to control 
the gene expression. In stable transfection, the 
DNA is introduced into cells long-term. The 
plasmid used for transfection contains the gene 
of interest and a blasticidin resistance gene. 
Selection is possible through blasticidin 
treatment, because of the blasticidin resistance 
gene. The process of transfection can be seen 
in Figure 16.  
For this project the transfection was prepared 
by plating cells at a density of 3x105 per well in 
6-well plates for 24 hours. Hereafter they were 
ready for transfection, which was conducted 
with three different plasmids; pCMV-EGFP, pcDNA6V5-HIS-A-EGFP and pcDNA6-NDRG2L-V5. 
Transfection mastermix was prepared by diluting 1 μg of plasmid in 100 μL McCoy’s 5A medium. 2 
μL gently vortex Turbofect Transfection Reagent (Thermo Scientific, #R0539) was added to the 
diluted plasmid. The transfection mastermix was resuspended and incubated at RT for 20 minutes. 
100 μL Transfection mastermix was added drop-wise to each well, and the plate was gently 
rocked. The plate was then incubated at 37°C with 5% CO2.  
Figure 16 shows the transfection step by step [Ibidi, 2014] 
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After 24 hours, the transfection was controlled and medium changed to ensure the best growth 
conditions for the cells. Control of the transfection was performed by use of fluorescence 
microscopy (Leica DMIRB) and the cells tranfected with the pCMV-EGFP plasmid. Hereafter, the 
transfected cells were grown in a selected medium for at least 14-21 days, and 12 μL (1mg/ml) 
blasticidin S HCI (Invitrogen, #46-1120) was used for selection.  
When the cells had been exposed to the selection factor for sufficient time, they were harvested 
by the followed procedure: washing with 1 ml PBS, trypsinizing with 100 μL trypsin for 5 minutes, 
resuspension in 900 μL McCoy’s 5A medium, and again resuspended in 1 ml PBS and spun down at 
14000 rpm for 5 minutes. Supernatant was removed and the pellet was stored at -80°C.  
3.4.2 Whole cell protein extraction  
To isolate protein from whole cells, a whole cell protein extraction method was used. All steps 
were performed on ice.  
Lysis Buffer++ was prepared using 1 ml Lysis Buffer (see Appendix I for the lysis buffer solution), 2 
μL 0.5M DTT, and 2 μL protease inhibitor (Sigma-aldrich, #P8340). The cell pellet was resuspended 
in 30 μL Lysis Buffer++ and incubated on ice for 30 minutes. Then the sample was spun down at 
14000 x g for 10 minutes at 4°C. Supernatant containing the protein fraction was transferred to a 
new tube and stored at -80°C until use.  
3.4.3 Western Blot  
Western Blotting is used to investigate the expression of a specific protein. Proteins are separated 
by size through gel electrophoresis. Proteins are then transferred to a membrane, and by using 
primary and secondary antibodies the proteins can be detected by the chemiluminescent 
detection method. The western blot is incubated with substrate that will luminesce when exposed 
to the reporter on the secondary antibody, and by use of Biospectrum® imaging system (UVP) the 
light makes the protein visible, see Figure 17. 
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3.4.4 Protein measurement  
Protein content was measured by use of Bradford standard curve assay. Bradford is an acidic 
solution of Coomassie Brilliant Blue dye, which interacts with the protein and changes the 
absorbance from 465 nm to 595 nm. This absorbance shift can be measured by a 
spectrophotometer to determine the protein concentration in the samples. The standard curve 
was prepared based on known concentrations of Bovine Serum Albumin (BSA). The concentration 
of unknown proteins can be determined by the absorbance given from the standard curve at 
known concentrations. See Appendix I for the Bradford solution.  
The standard curve was established by: 1 ml Bradford solution and varied concentrations of BSA of 
0, 1, 2, 4, 6, and 8 μg/μL. All samples were prepared in duplicates and incubated in darkness for 10 
minutes. The concentrations were then measured at the spectrophotometer (Biophotometer from 
eppendorf) at 595 nm.  
Protein samples with unknown concentrations could now be measured. All samples were 
prepared by adding of 1 ml Bradford solution and 2 μL protein lysate. A blank sample was 
prepared by use of 2 μL Lysis Buffer instead of protein. Then all samples were incubated at 10 
minutes in complete darkness and measured on the spectrophotometer at 595 nm.  
3.4.5 Separation of proteins by gel electrophoresis  
All protein samples were prepared by mixing 30 μg protein, 3.75 μL 4X Nupage® LDS sample Buffer 
(Invitrogen, #46-5030), 1.5 μL 0.5M DTT, and H2O to a total of 15 μL. Nupage® LDS sample Buffer 
had been incubated at 30°C before use. Before loading the gel, all samples were heated at 70°C for 
Figure 17 shows the antibody binding 
and the luminesce of light [Advansta, 
2014] 
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10 minutes. Nupage® 4-12% Bis-Tris Gel (Novex, #NP0322BOX) was prepared while the samples 
were heated. First, the comb was gently removed from the wells, then the wells were washed by 
deionized water and the tape was peeled off. The gel was placed in an XCell Surelock System and 
the chambers were filled with Running Buffer. The samples and markers were loaded and the gel 
was run at 200V for 1 hour. The marker used was PageRuler™ prestained protein ladder 
(Fermentas, #SM1811). 
3.4.6 Transfer of proteins by electro-blotting 
The membrane was prepared before the end of the gel run. All blotting pads were soaked in 
Transfer Buffer. The membrane was soaked in 96% ethanol for 30 sec, flushed with deionized 
water, and then placed in the transfer buffer until use.  
After the gel electrophoresis, the gel was separated from the cassette and the XCell II Blot module 
was prepared. All blotting pads were squeezed to remove air bubbles, filter paper was soaked in 
transfer buffer shortly before use, and blotting pads, filter paper, membrane, and gel was pressed 
together in layers as illustrated in Figure 18.  
 When the XCell II Blot Module was prepared, it was filled with Transfer buffer and ran at 25V for 1 
Hour.  
 
Figure 18 shows the composition in the XCell II Blot Module  
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3.4.7 Antigen binding  
After transfer, the membrane was separated in two. Both parts were loaded with the same 
samples, and detection of two different proteins could therefore be made at the same time. 
Membranes were washed briefly in transfer buffer and then incubated in 20 ml blocking buffer for 
30 minutes at RT. A rocking table was used at all steps to ensure full cover of the membranes. 
Membranes were then washed 2 x 2 minutes in 20 ml Wash buffer. The primary antibody was 
diluted in Dilution buffer and then added to the membranes after wash. The membranes were 
incubated overnight with the primary antibodies at 4°C. All solutions can be found in Appendix I. 
The secondary antibody was also prepared and diluted in Dilution buffer. The next day, the 
membranes were washed 2 x 10 minutes in 20 ml Wash buffer. The secondary antibody was 
added, and the membranes were incubated for 1 hour at RT. After incubation the membranes 
were washed 4 x 10 minutes in 20 ml Wash buffer. Antibodies and dilutions can be found in 
appendix I.  
3.4.8 Protein detection  
To detect the proteins the membranes were incubated for 10 minutes with 1 ml SuperSignal ® 
West Dura Extended Duration Substrate mix (Thermo Scientific, #34076) for each membrane. In 
order to obtain the best results, the incubation had to be performed in completely darkness and 
the proteins were detected by photography of the membranes by use of Biospectrum® imaging 
system (UVP).  
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3.5 Quantification of cell proliferation under varied conditions  
The description of growth assays can be found in the follow section. 
 The growth assays were performed with cancer cell line SW480 with both +/- NDRG2 expression 
and +/- IL-6 treatment. Only the cell line SW480 was selected for further work, based on the 
undetectable level of NDRG2 expression in transfected HCT116 cells.     
3.5.1 Growth assay for transfected cancer cell line SW480 
The growth rate for the transfected cancer cell line SW480 (pcDNA6V5-His-A-EGFP plasmid) and 
SW480 (pcDNA6-NDRG2L-V5 plasmid) were analyzed to define the growth of the cell line without 
NDRG2 and with NDRG2. Because the pcDNA6V5-His-A-EGFP plasmid does not contain NDRG2, 
the cells are considered to grow as normal SW480 cells. All cells were plated at a density of 1x104 
cells per well in 24-well plates, and all samples were conducted in triplicates. The cells were 
harvested and counted over a time period from 24-168 hours. The counting was performed by use 
of Beckmann Coulter Z2 Particle Count and size Analyzer, which had to be cleaned before use by 
primer and flushed with 10 ml 0.9 % biological salt water. Hereafter a blank sample consisting of 
10 ml 0.9 % biological salt water was counted, and now the unknown samples consisting of 200 μL 
sample diluted in 10 ml 0.9 % biological salt water could be counted.  
3.5.2 Growth assay for transfected cancer cell line SW480 treated with IL-6  
The growth rates for the transfected cancer cell line SW480 (pcDNA6-NDRG2L-V5 and pcDNA6V5-
His-A-EGFP plasmid) were analyzed in order to define the effect of IL-6 with NDRG2 and without. 
The cells were plated in duplicate at a density of 1x104 cells per well in 24-well plates. After 24h 
the cells were treated with IL-6 and set to grow for a further 24h, 96h, and 168h before being 
harvested. The counting was performed by use of Beckmann Coulter Z2 Particle Count and size 
Analyzer as described above.  
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3.6 Statistic  
Some of the results could be evaluated through statistical tests, and student’s t-test and F-test 
were used. The F-test is used to compare the variance between two data sets and can only be 
used in normal distributed populations, and high values of F indicate a difference between the 
dispersions in the two populations. All F-values over 0.05 were not significant and reversed. The 
student’s t-test can be used to study whether average values in two populations can be presumed 
to be identical. It is a condition for the use of the t-test that the populations are normal 
distributed. Different t-tests are available depending on the result of the F-test. If the variance was 
significant for the F-test, the populations were assumed to be equal. Thereby two different t-tests 
were available; paired t-test for two populations with equal variance, and unpaired t-test for two 
populations without equal variance. Both were used in this study and like the F-test, all t-values 
above 0.05 were considered not significant. 
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4. Results  
Results obtained in order to evaluate the hypotheses of the study are examined and analyzed in 
the following sections.  
4.1 NDRG2 expression in cancer cell lines SW480 and HCT116 at the mRNA 
level  
Previous studies have reported a down-regulation of NDRG2 expression in colorectal cancer and 
several other types of cancer [Chu et al., 2011; Hu et al., 2004; Lee et al., 2008; Lorentzen et al., 
2007; Piepoli et al., 2009; Lorentzen et al., 2011; Zhao et al., 2008; Ma et al., 2008;  Wang et al., 
2012], and therefore it could be interesting to examine if the same tendency could be seen in 
human cancer cell lines SW480 and HCT116. This result was important for further analyzes 
through the study and was analyzed by use of qRT-PCR. 
To be able to evaluate the NDRG2 expression level in the cell lines, a tissue with a known high 
expression of NDRG2 was used for normalization. Normal brain tissue was selected for the 
normalization, because brain tissue express high levels of NDRG2 [Deng et al., 2003]. A reference 
gene, RPLP0, was used and worked as an invariable endogenous control. The results of the 
examination of NDRG2 mRNA expression in the cell lines SW480 and HCT116 are illustrated in 
Figure 19.  
 
Figure 19 shows the expression levels of NDRG2 mRNA in cancer cell lines SW480 and HCT116 normalized to normal brain tissue. 
Columns represent the fold expression of NDRG2 mRNA expression. Standard deviations are included on the graph    
When the expression of NDRG2 mRNA was compared with normal brain tissue levels, the results 
show low expression of NDRG2 mRNA in cell lines SW480 and HCT116. In order to evaluate the 
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obtained results, a student’s t-test was used to analyze the observed difference between normal 
brain tissue and the cell lines and to conclude if the difference was significant. All calculated p-
values can be seen in Table 5, and all values below 0.05 mean that the differences were significant. 
Based on the observed results and p-values, NDRG2 mRNA expression was significantly lower in 
both cell lines when compared to normal brain tissue.       
 
 
 
Table 5 shows the p-values for the student’s t-test. Down-regulation of NDRG2 were significant for both cell lines, because of p-
values below 0.05  
4.2 NDRG2 expression in cancer cell lines SW480 and HCT116 at the 
protein level  
Previous studies have reported decreased levels of NDRG2 protein in different cancer types and 
cancer cell lines. The precise biological function of the NDRG2 protein is still unknown, but 
expression of NDRG2 protein has been observed to decrease the growth of cancer cells [Kim et al., 
2009]. Even though NDRG2 mRNA was low in both cell lines, this may not affect the expression of 
NDRG2 protein. Therefore, it was of interest to examine the levels of NDRG2 protein in both cell 
lines to see if the same tendency, as seen in previous studies, exists in these cell lines. 
Furthermore, the presence of NDRG2 was important for analyses of the growth rates of the cell 
lines.  
The protein level of NDRG2 could be examined and evaluated through extraction of total protein 
from both cell lines and western blotting. Before the cell lines could be examined and evaluated, 
they was transfected with an empty plasmid, pcDNA6V5-His-A-EGFP, which was assumed not to 
effect the normal NDRG2 protein level. This assumption could be confirmed by western blotting. 
The plasmid was constructed with a V5 and histidine-tag, which is approximately 2000 dalton ≈ 2 
kilodalton (kDa), and this construction made it possible to perform the analyses with both NDRG2- 
and V5 specific antibodies. The samples of interest were named by the cell lines name with V5 
added in the end. One positive control was included, which has previously shown NDRG2 protein 
Cell line p-value  
SW480 2.4 x 10-15 
HCT116 1.1 x 10-17 
 56 
expression. The results of the western blotting with specific NDRG2- and V5 antibodies are 
illustrated below in Figure 20.   
 
 
 
 
 
 
Membrane A was analyzed with specific NDRG2 antibody, and if the cell lines expressed NDRG2 
protein, the expected band would appear at approximately 41 kDa. All samples in membrane A 
named with a V5 in the end did not show any bands at all, which means that both cell lines did not 
express NDRG2 protein, and that the empty vector pcDNA6-V5-HIS-A-EGFP did not affect the 
expression of NDRG2. Furthermore, the positive control only showed a clear band at the 
approximate size for NDRG2. Membrane B was analyzed with a specific V5 antibody, but because 
the V5-His-tag is only around 2 kDa it is not visible and therefore no bands were expected. Again 
the samples with a V5 in the end were of interest, and the result of the analysis with the specific 
V5 antibody did not show any bands as expected.  
Based on these results it must be concluded that neither of the cell lines express NDRG2 at the 
protein level, and therefore a transfection with a plasmid containing NDRG2 was necessary for 
further analysis of how the presence of NDRG2 protein affects the growth rate, and how IL-6 
treatment affects the NDRG2 expression.    
 
 
Figure 20 shows the two membranes from the Western blotting result with SW480 and HCT116 cells. Picture A, shows the 
membrane analyzed with NDRG2 specific antibody and Picture B, shows the membrane analyzed with V5 specific antibody 
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4.3 Analysis of the most efficient concentration and time for the treatment 
with IL-6 
In order to optimize the treatment with IL-6, the cell lines were treated with different 
concentrations over a given time period. This was important for optimal treatment of the cell 
lines, when the effect of IL-6 on NDRG2 expression and growth rate was evaluated.  
In order to find the most efficient concentration and time, the following concentrations of 10 ρM, 
50 ρM, and 10,000 ρM of recombinant human IL-6 were used over a time period of 72 hours. 
When IL-6 is used for treatment, it is known to affect the activation of the JAK/STAT pathway, 
which normally leads to increased expression of Mcl-1 [Grivennikov et al., 2009; Jourdan et al., 
2003]. Therefore, to be able to estimate the efficiency of the IL-6 treatment, the mRNA expression 
level of Mcl-1 in human cancer cell lines SW480 and HCT116 was also analyzed. In preparation, 
cDNA was synthesized and then analyzed by qRT-PCR. The expression levels of Mcl-1 were 
normalized to RPLP0.  
 
Figure 21 shows the expression levels of IL-6 mRNA in cancer cell lines SW480 at different concentrations and times. Columns 
represent the fold expression of Mcl-1 mRNA expression. Standard deviations are included.  
The obtained levels of Mcl-1 mRNA after treatment of SW480 cells with different IL-6 
concentrations are illustrated in Figure 21. The highest fold increase of Mcl-1 mRNA expression 
was observed after treatment with 10,000 ρM of IL-6 for 72 hours.  
When HCT116 cells were treated with different concentrations of IL-6, the obtained levels of Mcl-1 
mRNA were different from the result with SW480 cells. The results are illustrated in Figure 22 
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below, and they show that HCT116 cells express more Mcl-1 mRNA, when treated with 50 ρM of 
IL-6 for 72 hours.  
 
Figure 22 shows the expression levels of IL-6 mRNA in cancer cell lines HCT116 at different concentrations and times. Columns 
represent the fold expression of Mcl-1 mRNA expression. Standard deviations are included 
Therefore, all further treatments of the cell lines SW480 and HCT116 were made with 10,000 ρM 
for SW480 cells and 50 ρM for HCT116 cells respectively in order to obtain the most efficient 
treatment.   
4.4 NDRG2 expression in treated cancer cell lines SW480 and HCT116 at 
mRNA level 
Association between IL-6 and colon cancer has been observed in previous studies, where elevated 
levels of IL-6 in serum were reported in patients with colon cancer and have been further 
connected with prognosis and survival. Furthermore, IL-6 has been connected with promotion of 
proliferation and invasion in colon cancer [Hsu et al., 2011; Nikiteas et al., 2005; Chung & Chang, 
2003; Hsu & Chang, 2006; Becker et al., 2004]. All these connections together with the observed 
functions of NDRG2 in colon cancer, makes it interesting to examine if NDRG2 expression is 
affected by elevated levels of IL-6.   
The expression of NDRG2 mRNA was evaluated in both cell lines when treated with appropriate 
concentrations of recombinant human IL-6. Expression levels of NDRG2 mRNA in treated cell lines 
were examined using qRT-PCR to evaluate if IL-6 treatment had any influence on the expression 
level of NDRG2 mRNA. All expression levels were normalized to the reference gene, RPLP0. The 
results of the qRT-PCR analysis are illustrated in Figure 23.  
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Figure 23 shows the expression levels of NDRG2 mRNA in cancer cell lines SW480 and HCt116 treated and untreated with IL-6. 
Columns represent the fold expression of NDRG2 mRNA expression. Standard deviations were included in the figure  
The results of the analyses show that the expression of NDRG2 mRNA in both cell lines was 
increased after treatment with IL-6.  To evaluate if the observed increase was significant, a 
student’s t-test was used. The p-values for both cell lines show that the small increases observed 
in NDRG2 mRNA expression for treated cells were not significant, when compared with untreated 
cells. The p-values can be seen in Table 6.  
 
 
 
Table 6 shows the p-values. All values over 0.05 indicate no significantly difference between treated and untreated SW480 and 
HCT116 cell lines 
These results indicate that elevated IL-6 levels in both cell lines did not affect the expression of 
NDRG2 mRNA levels.  
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4.5 Analysis of transfection efficiency  
The results of western blotting with an empty plasmid showed that none of the cell lines express 
NDRG2 protein. In order to examine if the presence of NDRG2 affects the growth rate in the cell 
lines, both cell lines were therefore transfected with the following plasmids; pcDNA6V5-His-A-
EGFP, pcDNA6-NDRG2L-V5, and pCMV-EGFP. A plasmid containing enhanced green fluorescence 
protein (EGFP) was used to verify transfection efficiency. EGFP functions as a powerful reporter 
molecule for estimation of transfection efficiency. All cells who have obtained the plasmid will 
fluoresce, when exposed to light by a fluorescence microscope camera at 470 nm. A picture of 
cells transfected with pCMV-EGFP plasmids is shown in Figure 24. 
 
 
 
 
 
 
The protocol for the transfection kit recommends transfection efficiency of minimum 10% before 
the work with the cells continues. When cells were exposed to fluorescence, around 40% were 
positive for fluorescence, and the transfection efficiency was approved for further work.  
4.6 Analysis of NDRG2 protein level after transfection  
In order to evaluate if the transfection had been successful, the protein level of NDRG2 was 
analyzed through western blotting. If the cell lines do not express any NDRG2 protein, it does not 
necessarily mean that the transfection was unsuccessful, because the plasmid can be incorporated 
in parts of the genome, which are not activated. Then no NDRG2 protein will be detectable, but it 
is possible to perform selections, which show if the plasmid has been obtained. The result was 
important for further analysis in order to evaluate the effect of the presence of NDRG2 in the cell 
Figure 24 shows pictures of the EGFP-transfected cell samples obtained with and without a fluorescence 
microscope, the two pictures are not from the same day and comparison cannot be made   
 61 
lines. In this western blot, only plasmid pcDNA6-NDRG2L-V5 was examined because of the 
conduction with NDRG2. The plasmid contained the long version of NDRG2 protein and was 
approximately 41 kDa. A V5-his-tag was coupled to NDRG2L and functioned as positive control for 
the presence of NDRG2. Therefore, proteins detected with a specific V5 antibody were expected 
to be approximately the same size as proteins detected with a specific NDRG2 antibody. The 
results of the western blot can be seen below in Figure 25, which includes both membranes 
analyzed with NDRG2 antibody and V5 antibody, respectively. The samples of interest were named 
with NDRG2 in the end.  
 
 
The results of the analysis with specific NDRG2 antibody are shown in membrane A and only the 
sample with SW480 cells showed an intense band at approximately 40-45 kDa, which was 
consistent with the expected size of NDRG2 protein. The fact that the sample with HCT116 cells 
did not show any band does not necessarily mean that the transfection was not successful, which 
was based on a successful selection. This can be explained by the fact that the plasmid with 
NDRG2 could be taken up by the cells without being activated in the genome. Membrane B was 
analyzed with a specific V5 antibody, where the V5-tag coupled to NDRG2L function as a positive 
control for the presence of NDRG2. This analysis showed the same observations as seen in 
membrane A and the only difference was that the observed band for the sample with SW480 cells 
Figure 25 shows the result of western blotting and all samples named with N (NDRG2) are of interest. The picture 
(A) show the membrane analyzed with NDRG2 antibody and picture (B) show the membrane analyzed with V5 
antibody. Only samples named with NDRG2 in the end are of interest  
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was weaker when analyzed with the V5 antibody, but approximately the same size as NDRG2 
protein.  
Because HCT116 cells did not express NDRG2 protein after the transfection, all further work was 
continued with SW480 cells expressing NDRD2 protein.  
4.7 Growth assays comparing cancer cell lines SW480 growth rate +/- 
NDRG2   
To examine if the presence of NDRG2 in the cells affect the growth rate, growth assays were 
performed with transfected SW480 cells +/- NDRG2 in order to compare the growth rates. In 
previous studies, the presence of NDRG2 has been associated with decreased growth, and 
therefore it would be interesting to see if the same observations could be seen in SW480 cells.  
Transfected SW480 cells +/- NDRG2 were grown over a time period at 168 hours and counted 
every day. Figure 26 illustrates the growth rates for transfected SW480 cells +/- expression of 
NDRG2. The highest increase in growth rate was observed after 168 hours. The observed 
difference in growth rates was around 60 % after 168 hours of growth, when the growth rates for 
SW480 cells +/- NDRG2 were compared.  
 
Figure 26 shows the result for the growth assay performed with SW480 cell line +/- NDRG2. Small standard deviations are 
illustrated 
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The measured p-values further support the results illustrated in Figure 26 by showing a significant 
difference in growth rates between SW480 cells +/- NDRG2, see Table 7. The significant difference 
was first observed after 96 hours and up to 168 hours.  
 
 
 
 
 
 
 
Table 7 shows the F-values and p-values for SW480 growth assay +/- NDRG2. Significant differences (values under 0.05) are seen 
for the cells growing over 96 hours up to 168 hours 
Therefore, the conclusion of the growth assay is that cells with NDRG2 show increased growth 
rate, when compared with cells without NDRG2.  
4.8 Growth assays comparing growth rates for SW480 cells untreated or 
treated with IL-6  
Based on the knowledge from previous studies, which have shown a correlation between 
increased levels of IL-6 and proliferation in colon cancer, it would be interesting to examine if IL-6 
affects the growth rate of SW480 cells.  
The cell line was treated with a concentration of IL-6 selected based on knowledge from previous 
analyses in this study, over a time period at 168 hours. Figure 27 illustrates the results of the 
growth assays, where the highest increase was observed after 96 hours of treatment and a smaller 
increase was seen after 168 hours of treatment. Treatment of the cells at 24 hours did not show 
any difference in growth rates, which indicate that IL-6 does not have any effect on the growth 
rate, when treated for less than 24 hours.  
Hours of growth  p-value 
24 0.408 
48 0.052 
72 0.241 
96 0.003 
120 6.2 x 10-4 
144 0.001 
168 5 x 10-4 
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Figure 27 shows the result of the growth assay with untreated and treated SW480 cells. Small standard deviations were seen   
The p-values show that the observed increase in growth rates after 96 and 168 hours in treated 
SW480 cells was significant, when compared with untreated SW480 cells, see Table 8.  
Hours of growth  p-value 
24 0.318 
96 0.003 
168 0.022 
Table 8 shows the P-values for untreated and treated SW480 cells  
Therefore it can be concluded that treatment of SW480 cells with IL-6 does affect the proliferation 
significantly after at least 96 hours of treatment.  
4.9 Growth assay comparing transfected cancer cell line SW480 treated 
and untreated with IL-6   
In order to examine how SW480 cells grow in the presence of NDRG2 and elevated levels of IL-6, 
the transfected cells were treated with IL-6 and comparison of the growth rates were made with 
untreated SW480 cells. In previous analyses through this study, both NDRG2 and IL-6 were 
observed to increase the growth rates, and the same concentration as previously was used for the 
treatment over a time period at 168 hours.  
The results of this growth assay are illustrated in Figure 28, where an increased growth rate was 
observed for transfected SW480 cells after at least 96 hours of treatment with IL-6. The biggest 
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difference between untreated and treated SW480 cells was seen after 96 hours, and the highest 
increase was observed after 168 hours of treatment, which was confirmed by the p-values 
showing significant difference between treated and untreated SW480 cells at all times, see Table 
9.  
 
Figure 28 shows the results for growth assays with SW480 cells containing NDRG2 and treated with and without IL-6. Small 
standard deviations are illustrated 
This indicates that the presence of NDRG2 together with treatment with IL-6 increases the growth 
rate significantly for SW480 cells.  
Hours of growth  p-value 
24 0.049 
96 1 x 10-5 
168 0.0001 
Table 9 shows the p-values  
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4.10 Short summary  
Based on the results in this section, it was observed that both SW480 and HCT116 cells did not 
show natural expression of NDRG2 at both mRNA and protein level, and further that treatment 
with IL-6 did not affect the expression of NDRG2 at mRNA level. Through transfection with a 
plasmid containing NDRG2 it was possible to get SW480 cells to express NDRG2 protein, which 
was required for most of the remaining analyses through this study. The presence of NDRG2 in 
SW480 cells affected the growth rate by increasing it, and the same tendency was observed in 
SW480 cells treated with IL-6, which did not express NDRG2. Furthermore, the presence of NDRG2 
and increased levels of IL-6 combined affected the growth rate for transfected SW480 cells by 
increasing the proliferation.     
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5. Discussion  
Cancer is a leading cause of death, and more than 30 million people are living with the disease 
worldwide [WHO, 2014]. Therefore research of the molecular mechanisms behind tumorigenesis 
is of great importance in order to elucidate, how to treat and prevent the events of tumorigenesis. 
Various mechanisms have been connected to cancer development and growth including emerging 
hallmarks and enabling characteristics, which describe the relationship between the immune 
system and cancer and genomic changes behind tumorigenesis [Hanahan & Weinberg, 2011]. One 
of the genomic aspects in cancer development is tumor suppressor genes, such as the newly found 
tumor suppressor gene, NDRG2, which has been reported to be down-regulated in several cancer 
types and epigenetically modulated [Piepoli et al., 2009; Chu et al., 2011; Hu et al., 2004; Lee et 
al., 2008; Lorentzen et al., 2007; Piepoli et al., 2009; Lorentzen et al., 2011; Zhao et al., 2008; Ma 
et al., 2008; Wang et al., 2012]. Other important mediators of tumorigenesis are inflammatory 
factors including the cytokine IL-6, which has been connected with induction of progression, 
growth, and invasiveness in human colon carcinoma [Hsu et al., 2011; Hsu & Chung, 2006]. 
Through this study human cancer cell lines HCT116 and SW480 were used to validate the 
previously observed down-regulation of NDRG2 in colon cancer, and further to investigate if IL-6 
had any impact on the NDRG2 expression and growth rate.  
5.1 The demonstration of the observed down-regulation of NDRG2 
expression 
In both cells lines, the NDRG2 expression at mRNA level was compared with the expression in 
normal brain tissue. In previous studies with colon cancer tissue and different cell lines, a down-
regulation of the NDRG2 expression had been reported [Feng et al., 2011; Lorentzen et al., 2007; 
Chu et al., 2011; Kim et al., 2009]. Consistent with these findings obtained by other groups, the 
result of this study showed a significantly lower NDRG2 expression in HCT116 and SW480 cancer 
cell lines, when compared to normal brain tissue. A possible explanation of the observed low 
expression of NDRG2 could be the elevated evidence of transcriptional silencing of NDRG2 
through hypermethylation of NDRG2 promoter region [Feng et al., 2011]. Furthermore, studies 
with colon cancer have shown a significant increase of NDRG2 mRNA expression after treatment 
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with a demethylating agent, which indicates that methylation, can affect the expression of NDRG2 
mRNA [Piepoli et al., 2009; Feng et al., 2011].  
Proteins have many distinct biological functions. They are the resulting product of the gene 
expression, and therefore the protein expression of NDRG2 is of interest. In order to investigate 
the protein level, protein extraction was performed and analyzed by western blotting. The 
obtained results show that none of the cell lines express NDRG2 protein, and this observation is 
supported by other studies with colon cancer cells [Shi et al., 2009; Lorentzen & Mitchelmore, 
2012]. miRNAs have been connected with regulation of gene expression through 
posttranscriptional silencing by binding to the 3’ untranslated region of mRNA [Baer et al., 2013; 
Sharma et al., 2010]. Feng et al. have investigated miRNAs impact on the expression of NDRG2 and 
found that down-regulation of NDRG2 was inversely associated with up-regulation of miRNAs 
[Feng et al., 2011]. This may indicate a possible role in aberrant expression of NDRG2 mRNA and 
protein, because of miRNAs ability to inhibit protein synthesis and RNA degradation [Baer et al., 
2013; He & Hannon, 2004]. Furthermore, miRNAs have been associated with biological processes 
as proliferation, apoptosis, and differentiation, also supporting a potential role in tumorigenesis 
[Saito & Jones, 2006].  
5.2 Possible impact of IL-6 on the expression of NDRG2  
In order to elucidate the impact of IL-6 on NDRG2 expression, both cell lines were transfected with 
plasmid (pcDNA6-NDRG2L-V5) containing NDRG2 to ensure NDRG2 expression and then treated 
with recombinant human IL-6. The doses used were determined and modified based on a previous 
published study, where the authors have treated colon cancer cells with IL-6 [Hsu & Chung, 2006]. 
As already mentioned IL-6 functions as a key activator of the JAK/STAT pathway leading to 
activation of transcription factor STAT3. The expression of Mcl-1 was used to measure the 
efficiency of the treatment with IL-6, because Mcl-1 expression is induced by STAT3. The most 
efficient doses for treatment of both cell lines were high, when compared with normal levels of IL-
6 in humans. Becker et al. have showed that treatment with hyper-IL-6 (IL-6 and covalently linked 
soluble IL-6 receptor) affect proliferation and phosphorylation of STAT3. Additionally, they showed 
a down-regulation of IL-6R in colon cancer patients [Becker et al., 2004]. This down-regulation of 
 69 
IL-6R may affect the activation of the JAK/STAT pathway and thereby the expression of Mcl-1, 
which could explain the necessity of high doses of recombinant human IL-6 for treatment.  
NDRG2 expression has been reported to modulate SOCS3 and STAT3 activity and inhibit the 
production of the cytokine IL-10, which is strongly connected with IL-6 through the JAK/STAT 
pathway [Lee et al., 2010; Hamidullah et al., 2012]. Because of the important role of IL-6 in the 
activation of the JAK/STAT pathway, it may also be involved in the production and regulation of IL-
10 [Lee et al., 2010]. No studies have investigated IL-6 impact on NDRG2 expression in cancer, and 
for that reason the results of this experiment are completely unknown. In both cell lines a small 
increase in NDRG2 mRNA were observed after the treatment with IL-6, but the observation were 
not significant. This may indicate that IL-6 does not have an influence on the regulation of NDRG2 
expression, but further knowledge of NDRG2’s impact on IL-6 is needed to be able to elucidate a 
possible connection.  
5.3 The growth rate of cancer cell lines and the influence of NDRG2 
expression   
To investigate how NDRG2 expression affects the growth of colon cancer cell lines, a growth assay 
was performed. Normally the NDRG2 expression is transcriptionally regulated by MYC, which is 
important for cell proliferation and differentiation [Dang et al., 2008; Wierstra & Alves, 2008]. In 
colorectal cancer an increase in the MYC level has been observed together with a decrease in 
NDRG2 expression, which may indicate that MYC is able to repress human NDRG2 [Shi et al., 
2009]. Furthermore, several studies with cancers have reported a down-regulation of NDRG2 and 
suppression of proliferation and induced apoptosis through regulation of cyclin D1 and T cell 
factor/β-catenin activity, all supporting a potential role for NDRG2 as an inhibitor of cancer cell 
proliferation [Shi et al., 2009; Lorentzen & Mitchelmore, 2012; Yao et al., 2008; Chu et al., 2011; 
Zheng et al., 2010; Liang et al., 2012]. The results of the growth assay does not consist with other 
observations, in that a significantly increased growth rate was observed in both cell lines, when 
NDRG2 was present. Because HCT116 did not show any protein expression of NDRG2 after the 
transfection, the result of the growth assay for this cell line was unclear. The increased growth 
rate for SW480 cell line may be explained by the fact that other studies with colon cancer cell lines 
have shown that an increase in expression of MYC leads to a decrease in the expression of NDRG2. 
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This may lead to increased growth rate, because NDRG2 expression has been correlated with 
proliferation [Shi et al., 2009; Zhang et al., 2006]. In order to evaluate this theory, the expression 
of MYC has to be examined in SW480 cells.  
5.4 The growth rate and the influence of IL-6 treatment  
To elucidate if IL-6 has an impact on the growth rate of the colon cancer cell line SW480, two 
growth assays were performed; one with the presence of NDRG2 and one without. Studies have 
shown an association between elevated levels of IL-6 in patients with colon carcinoma and tumor 
growth [Hsu et al., 2011; Hsu & Chung, 2006; Becker et al., 2004]. Also, IL-6 signaling regulates 
many cellular functions, including growth, differentiation, and angiogenesis, and IL-6 has been 
observed to increase the proliferation of colorectal carcinoma cells [Hirano et al., 2000; Jee et al., 
2004; Leu et al., 2003; Köbel et al., 2005; Lahm et al., 1992].  The results of the first growth assay 
with no expression of NDRG2 showed an increase in growth rate, when compared with untreated 
cells, and this result is consistent with other studies.  
The second growth assay was performed with cells expressing NDRG2 to investigate if IL-6 and 
NDRG2 together affect the growth rate. As mentioned earlier, NDRG2 is known to decrease the 
growth rate of colon cancer cells, while IL-6 has been shown to increase the growth rate 
previously in this study. The NDRG2-presenting cells treated with IL-6 showed a significant 
increase in growth rate, when compared to cells without NDRG2. Based on previous results in this 
study, both the presence of NDRG2 and treatment with IL-6 were expected to affect the growth 
rate positively by an increase in proliferation.  This is also consistent with the results. For further 
analyzes it would be necessary to performed growth assays with NDRG2-presenting cell lines 
treated with IL-6 and cell lines without NDRG2 present but still treated with IL-6 to investigate the 
exact role of NDRG2 in IL-6 treated cell lines.   
Through this study it was found that NDRG2 was down-regulated in colon cancer cell lines both at 
mRNA and protein level, that IL-6 did not affect the NDRG2 expression at the level of mRNA, that 
an increase in growth was seen both in cells with NDRG2 and treated with IL-6, and lastly that IL-6 
may affect the growth rate positively when NDRG2 is present.   
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6. Conclusion  
The present thesis has contributed with further evidence of the reported down-regulation of 
NDRG2 expression in colon cancer cell lines. In the human cell lines HCT116 and SW480, a 
significantly lower expression of NDRG2 was shown, when compared to expression levels in 
normal human brain tissue. These findings correlated with an undetectable level of NDRG2 protein 
in both cell lines. Treatment of both cell lines with IL-6 showed a small increase in NDRG2 mRNA 
expression, but the increase was not significant, and further research is necessary in order to 
investigate if IL-6 has an impact on NDRG2.   
When NDRG2 was expressed in the human cell line SW480 through transfection, an increase in 
growth rate was observed. These observations were not consistent with other studies, and they 
do not support the theory of NDRG2 as a potential tumor suppressor gene. However, this thesis 
was based on small experimental data sets, and this may affect the strength of the results. 
Additionally, treatment of the human cell line SW480 with IL-6 caused a significantly increased 
growth rate after 96 hours, which was consistent with other published results. In order to evaluate 
if IL-6 treatment and presence of NDRG2 affected the growth rate of human cell line SW480, a 
growth assay was performed and a significantly increased growth rate was observed, when NDRG2 
was present in the cell line and treatment with IL-6 had been performed. This may indicate a 
potential correlation between NDRG2 and IL-6, but further knowledge, larger experimental data 
sets, and more research are needed.    
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7. Perspectives  
At present, the exact mechanisms behind a possible connection between IL-6 and NDRG2 still 
remains unknown. To be able to elucidate this matter and examine a possible connection, further 
research and knowledge of both IL-6 and NDRG2s function in development, proliferation of cancer 
cells, and regulation are required. Several different cancer types have been associated with down-
regulated NDRG2 expression, whereas IL-6 has only been associated with a few types, including 
colon cancer. If the published findings of NDRG2 expressions involvement in the JAK/STAT 
pathway in breast cancer are correct, it might be possible to investigate if this involvement also 
appears to influence the progression of colon cancer cells. Additionally, NDRG2 expression has 
already been connected with decreased proliferation of colon cancer cells, whereas the levels of 
IL-6 have been reported increased in colon cancer cells.  
 
A possible extension of the present work would be to optimize the experiment of the impact of IL-
6 on the NDRG2 mRNA level by examining the expression level of NDRG2 mRNA in normal colon 
cancer cells in order to be able to compare the expression of NDRG2 mRNA with the presence in 
colon cancer cells. Hereafter, treatment with IL-6 could be performed to see if the treatment 
affects the expression of NDRG2 in normal colon cells. These studies would make it possible to 
examine, if IL-6 has an impact on the NDRG2 expression in colon cancer cells, and thus provide 
important information in order to develop new immunotherapeutic agents against colon cancer.       
 
Although an association between NDRG2 expression and IL-6 treatment was not supported by 
data obtained in the present thesis, findings in other studies indicate a potential role of TGF-β in 
the connection between NDRG2 and IL-6 in colon cancer. Therefore, it would be interesting to 
investigate if TGF-β affects NDRG2 expression and its function in inhibition of IL-6-trans signaling in 
colon cancer.  
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9. Appendices  
9.1 Appendix I  
Lysis Buffer 
200 μL 1M Hepes (PH 7.9) 
15 μL 1M MgCl2 
4.2 ml 1M NaCl 
2.9 ml 87% Glycerol 
2.7 ml Milli-Q water 
 
Bradford Reagent (AppliChem, 
#A3480,0010) 
200 mg Coomassie Brilliant Blue  
100 ml 96% Ethanol 
200 ml 85% Phosphoric acid  
Milli-Q water until 2 Liters 
 
Transfer Buffer (Life technologies, #NP0006-
1) 
50 ml 20X NuPAGE® Transfer Buffer  
200 ml 96% Ethanol 
 750 ml Milli-Q water 
 
Blocking Buffer (GE healthcare, #RPN2125V) 
5 % 20 ml PBS-T 
1 g Blocker 
 
Dilution Buffer 2.5% (GE healthcare, 
#RPN2125V) 
20 ml PBS-T 
0.5 g Blocker 
 
Running Buffer (Life technologies, #NP0001) 
50 ml 20X NuPAGE® MOPS SDS  
950 ml Milli-Q water 
 
PBS 10X (Ph 7.3) 
1.4 M NaCl  
27 mM KCl  
101 mM Na2HPO4  
18 mM KH2PO4 
 
TE-Buffer 
10 mM TrisCl (PH 8.0) 
1 mM EDTA 
TENS-Buffer: 
100 mM TrisCl (PH 8.5) 
5 mM EDTA 
200 mM NaCl 
0.2% SDS 
 
Wash Buffer (PBS-T 0.01%) (Sigma-Aldrich, 
#P2287) 
1 liter 1X PBS 
1 ml Tween-2
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Antigens Molecular 
Weight (kDa) 
Primary antibody/ 
Secondary antibody 
Dilution Supplier 
NDRG2 41 Goat polyclonal IgG/ 
Donkey IgG-HRP 
1:5000 Santa-Gruz Biotechnology, 
#sc-19568/Santa-Gruz 
Biotechnology, #sc2056 
V5 14 + 41 (NDRG2) Rabbit monoclonal IgG/ 
Goat IgG-HRP 
1:5000/ 
1:10000 
Sigma-Aldrich, #V8137/Pierce, 
#1858415 
Β-actin  42 Mouse monoclonal IgG/ 
Goat IgG-HRP 
1:5000 Sigma-Aldrich, #A5411/Pierce, 
#1858413 
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9.2 Appendix II 
Plasmid pCMV-EGFP 
 
Plasmid pcDNA6V5-His-A-EGFP 
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Plasmid pcDNA6-NDRG2L-V5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
